Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 748 articles:
HTML format



Single Articles


    July 2021
  1. WAN CL, Zou JY, Qiao M, Yin J, et al
    Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957876.
    PubMed    


  2. KOUTROUMANI M, Laidou S, Kotta K, Stamatopoulos K, et al
    TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-4. doi: 10.1080/10428194.2021.1957870.
    PubMed    


  3. SWEET K, Bhatnagar B, Dohner H, Donnellan W, et al
    A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 29:1-12. doi: 10.1080/10428194.2021.1950706.
    PubMed     Abstract available


  4. EL HUSSEIN S, Wang W, Wang SA, Loghavi S, et al
    Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon.
    Leuk Lymphoma. 2021 Jul 24:1-4. doi: 10.1080/10428194.2021.1957878.
    PubMed    


  5. PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
    Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
    Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
    PubMed     Abstract available


  6. WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
    A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
    Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
    PubMed     Abstract available


  7. DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
    Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
    PubMed     Abstract available


  8. BEYAN C
    Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 14:1. doi: 10.1080/10428194.2021.1953017.
    PubMed    


  9. GAO J, Fu L, Lu X, Sukhanova M, et al
    Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of TP53 mutation and genetic complexity.
    Leuk Lymphoma. 2021 Jul 14:1-4. doi: 10.1080/10428194.2021.1950710.
    PubMed    


  10. PAGNANO KB, Peralta EH, Navarro JR, David Salas LDR, et al
    COVID-19 in chronic myeloid leukemia patients in Latin America.
    Leuk Lymphoma. 2021 Jul 13:1-7. doi: 10.1080/10428194.2021.1950709.
    PubMed     Abstract available


  11. JIANG H, Liu XH, Kong J, Wang J, et al
    Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
    PubMed     Abstract available


  12. JINDAL N, Lad DP, Malhotra P, Prakash G, et al
    Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
    Leuk Lymphoma. 2021;62:1674-1681.
    PubMed     Abstract available


  13. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed     Abstract available


    June 2021
  14. STAHL M, Narendra V, Jee J, Derkach A, et al
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
    PubMed     Abstract available


  15. LEPRETRE S, Touboul C, Flinois A, Kutikova L, et al
    Quality of life in adults with acute lymphoblastic leukemia in France: results from a French cross-sectional study.
    Leuk Lymphoma. 2021 Jun 24:1-11. doi: 10.1080/10428194.2021.1941924.
    PubMed     Abstract available


  16. YOSHIMOTO G, Mori Y, Kato K, Odawara J, et al
    Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Jun 23:1-10. doi: 10.1080/10428194.2021.1941937.
    PubMed     Abstract available


  17. SINGH J, Facey A, O'Malley F, Ryland GL, et al
    Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941935.
    PubMed    


  18. HADJIAGGELIDOU C, Douganiotis G, Tsirou K, Verrou E, et al
    A rare case of autoimmune hemolytic anemia during venetoclax therapy for relapsed chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 21:1-3. doi: 10.1080/10428194.2021.1941932.
    PubMed    


  19. RAMKISSOON LA, Buhlinger K, Nichols A, Coombs CC, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment.
    Leuk Lymphoma. 2021 Jun 21:1-4. doi: 10.1080/10428194.2021.1941928.
    PubMed    


  20. BOLUDA B, Martinez-Cuadron D, Algarra L, Cano I, et al
    Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
    Leuk Lymphoma. 2021 Jun 14:1-10. doi: 10.1080/10428194.2021.1938031.
    PubMed     Abstract available


  21. KHAZAL S, Kebriaei P
    Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes.
    Leuk Lymphoma. 2021 Jun 3:1-14. doi: 10.1080/10428194.2021.1933475.
    PubMed     Abstract available


  22. STUBBINS RJ, Maksakov IA, Sanford DS, Rouhi A, et al
    Mitochondrial metabolism: powering new directions in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-11. doi: 10.1080/10428194.2021.1910685.
    PubMed     Abstract available


  23. BOULLAND ML, Vic S, Thonier F, Ganard M, et al
    Reliable IGHV status assessment by next generation sequencing in routine practice for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jun 1:1-4. doi: 10.1080/10428194.2021.1933476.
    PubMed    


  24. LADHA A, Hui G, Cheung E, Berube C, et al
    Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.
    Leuk Lymphoma. 2021;62:1510-1513.
    PubMed    


  25. SENAPATI J, Dhawan R, Aggarwal M, Kumar P, et al
    Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country.
    Leuk Lymphoma. 2021;62:1514-1517.
    PubMed    


  26. QU S, Jia Y, Wang H, Ai X, et al
    STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
    Leuk Lymphoma. 2021;62:1506-1509.
    PubMed    


    May 2021
  27. YURKIEWICZ IR, Coutre S, Ghesquieres H, Pastan I, et al
    Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
    Leuk Lymphoma. 2021 May 25:1-3. doi: 10.1080/10428194.2021.1929959.
    PubMed    


  28. CUMBO C, Tota G, De Grassi A, Anelli L, et al
    RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929960.
    PubMed    


  29. SHARMA P, Rana S, Virk H, Sachdeva MUS, et al
    The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
    Leuk Lymphoma. 2021 May 24:1-5. doi: 10.1080/10428194.2021.1929964.
    PubMed    


  30. JIN H, Zhu Y, Hong M, Wu Y, et al
    Co-occurrence of KIT and NRAS mutations defines an adverse prognostic core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2021 May 24:1-10. doi: 10.1080/10428194.2021.1919660.
    PubMed     Abstract available


  31. BAZINET A, Rys RN, Barry A, Greenwood CMT, et al
    A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 21:1-8. doi: 10.1080/10428194.2021.1919658.
    PubMed     Abstract available


  32. TIGLIOGLU M, Albayrak M, Dogan S, Yilmaz F, et al
    Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis.
    Leuk Lymphoma. 2021 May 20:1-7. doi: 10.1080/10428194.2021.1929962.
    PubMed     Abstract available


  33. HANDL S, von Heydebrand F, Voelkl S, Oostendorp RAJ, et al
    Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 17:1-11. doi: 10.1080/10428194.2021.1927019.
    PubMed     Abstract available


  34. LIANG D, Wei C, Zhang X, Yang J, et al
    Efficacy of lenalidomide for relapsed or refractory T lymphoblastic lymphoma/leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 May 17:1-5. doi: 10.1080/10428194.2021.1919665.
    PubMed    


  35. KUROSAWA S, Kaito S, Uchida N, Fukuda T, et al
    Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study.
    Leuk Lymphoma. 2021 May 12:1-7. doi: 10.1080/10428194.2021.1924374.
    PubMed     Abstract available


  36. DAVIDS MS, Telford C, Abhyankar S, Waweru C, et al
    Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naive chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 May 6:1-16. doi: 10.1080/10428194.2021.1913144.
    PubMed     Abstract available


  37. ADNAN-AWAD S, Kankainen M, Mustjoki S
    Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
    Leuk Lymphoma. 2021 May 4:1-15. doi: 10.1080/10428194.2021.1894652.
    PubMed     Abstract available


  38. MARQUES-PIUBELLI ML, Schlette EJ, Khoury JD, Furqan F, et al
    Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Leuk Lymphoma. 2021;62:1129-1135.
    PubMed     Abstract available


    April 2021
  39. WALLWITZ J, Aigner P, Stoiber D
    Tumor suppressors in acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 30:1-11. doi: 10.1080/10428194.2021.1907372.
    PubMed     Abstract available


  40. WANG M, Wang R, Wang H, Chen C, et al
    Difference in gene mutation profile in patients with refractory/relapsed versus newly diagnosed acute myeloid leukemia based on targeted next-generation sequencing.
    Leuk Lymphoma. 2021 Apr 29:1-12. doi: 10.1080/10428194.2021.1919661.
    PubMed     Abstract available


  41. WANG N, Yuan L, Jing Y, Fan K, et al
    Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype, TP53 deletion, and TP53 mutations.
    Leuk Lymphoma. 2021 Apr 27:1-9. doi: 10.1080/10428194.2021.1919663.
    PubMed     Abstract available


  42. REES MJ, Wu S, Mokoonlall M, Dix CHK, et al
    The real-world tolerability and efficacy of asparaginase in adults aged 40 years and older with Philadelphia-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-3. doi: 10.1080/10428194.2021.1919666.
    PubMed    


  43. ZHAN M, Chen ZB, Ding CC, Qu Q, et al
    Machine learning to predict high-dose methotrexate-related neutropenia and fever in children with B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Apr 26:1-12. doi: 10.1080/10428194.2021.1913140.
    PubMed     Abstract available


  44. GUPTA A, Gill S
    CAR-T cell persistence in the treatment of leukemia and lymphoma.
    Leuk Lymphoma. 2021 Apr 19:1-13. doi: 10.1080/10428194.2021.1913146.
    PubMed     Abstract available


  45. WALKER KL, Rinella SP, Hess NJ, Turicek DP, et al
    CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Leuk Lymphoma. 2021 Apr 11:1-11. doi: 10.1080/10428194.2021.1910684.
    PubMed     Abstract available


  46. FAZIO F, Quintini M, Carmosino I, Matteucci C, et al
    New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia.
    Leuk Lymphoma. 2021 Apr 9:1-4. doi: 10.1080/10428194.2021.1910689.
    PubMed    


  47. BENITEZ LL, Perissinotti AJ, Rausch CR, Klaus J, et al
    Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378.
    PubMed     Abstract available


  48. PASIC I, Paulson K, Dozois G, Schultz KR, et al
    Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.
    Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1910688.
    PubMed     Abstract available


  49. HIDALGO-GOMEZ G, Palacio-Garcia C, Gallur L, Blanco A, et al
    Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Apr 7:1-9. doi: 10.1080/10428194.2021.1907375.
    PubMed     Abstract available


  50. JOBSON D, McCormack CJ, Hiscutt E, Tam C, et al
    Severe treatment-resistant autoimmune haemolytic anaemia following ipilimumab in a patient with metastatic melanoma and CLL.
    Leuk Lymphoma. 2021;62:992-994.
    PubMed    


  51. HARROP S, Polliack A, Tam CS
    Chronic lymphoproliferative disorders and secondary cancers in the era of purine analogues and beyond.
    Leuk Lymphoma. 2021;62:771-778.
    PubMed     Abstract available


  52. PACOUREAU L, De Menthon M, Boytchev I, Lazure T, et al
    Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
    Leuk Lymphoma. 2021;62:984-987.
    PubMed    


    March 2021
  53. BONOMETTI A, Lobascio G, Boveri E, Cesari S, et al
    Acute megakaryoblastic leukemia with a novel GATA1 mutation in a second trimester stillborn fetus with trisomy 21.
    Leuk Lymphoma. 2021 Mar 30:1-4. doi: 10.1080/10428194.2021.1907377.
    PubMed    


  54. EPSTEIN-PETERSON ZD, Ganesan N, Barker JN, Drullinsky PR, et al
    Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
    Leuk Lymphoma. 2021 Mar 29:1-7. doi: 10.1080/10428194.2021.1897806.
    PubMed     Abstract available


  55. HOCHMAN MJ, Othus M, Walter RB, Shaw C, et al
    Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML).
    Leuk Lymphoma. 2021 Mar 22:1-4. doi: 10.1080/10428194.2021.1885658.
    PubMed    


  56. ELITZUR S, Frank S, Goshen-Lago T, Barzilai-Birenboim S, et al
    Long-term ovarian reserve and fertility outcomes in female survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 22:1-10. doi: 10.1080/10428194.2021.1901093.
    PubMed     Abstract available


  57. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 21:1-3. doi: 10.1080/10428194.2021.1901097.
    PubMed    


  58. BALAKRISHNA J, Basumallik N, Matulonis R, Scott D, et al
    Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma.
    Leuk Lymphoma. 2021 Mar 18:1-12. doi: 10.1080/10428194.2021.1894641.
    PubMed     Abstract available


  59. DE CARVALHO AC, Ogawa CY Junior, De Camillis Rodrigues L, de Medeiros LS, et al
    Penicillium genus as a source for anti-leukemia compounds: an overview from 1984 to 2020.
    Leuk Lymphoma. 2021 Mar 18:1-15. doi: 10.1080/10428194.2021.1897804.
    PubMed     Abstract available


  60. PEPE S, Scalzulli E, Colafigli G, Di Prima A, et al
    Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience.
    Leuk Lymphoma. 2021 Mar 16:1-6. doi: 10.1080/10428194.2021.1901094.
    PubMed     Abstract available


  61. PETTERSSON L, Holmgren B, Juliusson G, Lazarevic VL, et al
    Mutational spectrum of de novo NPM1-mutated acute myeloid leukemia patients older than 75 years.
    Leuk Lymphoma. 2021 Mar 12:1-9. doi: 10.1080/10428194.2021.1894650.
    PubMed     Abstract available


  62. DHAKAL P, Lyden E, Rajasurya V, Zeidan AM, et al
    Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials?
    Leuk Lymphoma. 2021 Mar 12:1-9. doi: 10.1080/10428194.2021.1894651.
    PubMed     Abstract available


  63. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Mar 10:1-3. doi: 10.1080/10428194.2021.1897807.
    PubMed    


  64. OTHUS M, Garcia-Manero G, Godwin J, Weick J, et al
    Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia.
    Leuk Lymphoma. 2021 Mar 10:1-6. doi: 10.1080/10428194.2021.1885663.
    PubMed     Abstract available


  65. XU W, Ye L, Mei C, Zhou XP, et al
    Decitabine combined with low dose idarubicin and cytarabine (D-IA) followed by allo-HSCT improves acute myeloid leukemia and higher-risk myelodysplastic syndrome patient outcomes: results from a retrospective study.
    Leuk Lymphoma. 2021 Mar 7:1-18. doi: 10.1080/10428194.2021.1891230.
    PubMed     Abstract available


  66. MAFFEI R, Fiorcari S, Atene CG, Martinelli S, et al
    A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
    Leuk Lymphoma. 2021 Mar 4:1-6. doi: 10.1080/10428194.2021.1894643.
    PubMed    


  67. DESAI S, Mo C, Gaglione EM, Yuan CM, et al
    Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study.
    Leuk Lymphoma. 2021 Mar 2:1-17. doi: 10.1080/10428194.2021.1888379.
    PubMed     Abstract available


  68. MARTINEZ-LOPEZ J, Mustjoki S, Porkka K, Klisovic RB, et al
    The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study.
    Leuk Lymphoma. 2021 Mar 2:1-7. doi: 10.1080/10428194.2021.1889536.
    PubMed    


  69. ROERDEN M, Marklin M, Salih HR, Bethge WA, et al
    Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
    Leuk Lymphoma. 2021 Mar 2:1-18. doi: 10.1080/10428194.2021.1885659.
    PubMed     Abstract available


  70. ATALLAH EL, Sadek I, Maegawa R, Cao X, et al
    Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.
    Leuk Lymphoma. 2021 Mar 1:1-14. doi: 10.1080/10428194.2021.1885656.
    PubMed     Abstract available


  71. TIMOFEEVA N, Gandhi V
    Metabolism meets apoptosis in AML.
    Leuk Lymphoma. 2021;62:514-516.
    PubMed    


  72. CHEN NC, Borthakur G, Pemmaraju N
    Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
    Leuk Lymphoma. 2021;62:528-537.
    PubMed     Abstract available


    February 2021
  73. FODIL S, Raffoux E, Dumas PY, Desbrosses Y, et al
    Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2021 Feb 17:1-7. doi: 10.1080/10428194.2021.1881505.
    PubMed    


  74. KHAN S, Durairaj S, Phumphukhieo P, Holding S, et al
    Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Feb 17:1-8. doi: 10.1080/10428194.2021.1885662.
    PubMed    


  75. PRZESPOLEWSKI A, Muppidi MR, Freyer CW, Ji W, et al
    Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG +/- M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
    Leuk Lymphoma. 2021 Feb 16:1-6. doi: 10.1080/10428194.2021.1885654.
    PubMed    


  76. RAMAN HS, Shanmugam V, Li J, Steensma DP, et al
    NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.
    Leuk Lymphoma. 2021 Feb 13:1-5. doi: 10.1080/10428194.2021.1881510.
    PubMed    


  77. ROBOZ GJ, Desai P, Lee S, Ritchie EK, et al
    A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2021 Feb 13:1-13. doi: 10.1080/10428194.2021.1881509.
    PubMed     Abstract available


  78. FREI CR, Le H, McHugh D, Ryan K, et al
    Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System.
    Leuk Lymphoma. 2021 Feb 11:1-14. doi: 10.1080/10428194.2021.1876863.
    PubMed     Abstract available


  79. BAK A, Skonieczka K, Jaskowiec A, Junkiert-Czarnecka A, et al
    Searching for germline mutations in the RUNX1 gene among Polish patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Feb 10:1-9. doi: 10.1080/10428194.2021.1881503.
    PubMed     Abstract available


  80. MOSELEY A, Othus M, Garcia-Manero G, Appelbaum FR, et al
    Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203.
    Leuk Lymphoma. 2021 Feb 9:1-7. doi: 10.1080/10428194.2021.1881512.
    PubMed    


  81. PEGLIASCO J, Schmaltz-Panneau B, Martin JE, Chraibi S, et al
    ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies.
    Leuk Lymphoma. 2021 Feb 7:1-8. doi: 10.1080/10428194.2021.1881508.
    PubMed    


  82. WAKSAL JA, Tallman MS
    Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.
    Leuk Lymphoma. 2021 Feb 4:1-26. doi: 10.1080/10428194.2020.1842403.
    PubMed     Abstract available


    January 2021
  83. BENJAMIN ESB, Ravindra N, Rajamani BM, Anandan S, et al
    BCR-ABL1 kinase domain mutation analysis by next generation sequencing detected additional mutations in chronic myeloid leukemia patients with suboptimal response to imatinib.
    Leuk Lymphoma. 2021 Jan 22:1-6. doi: 10.1080/10428194.2021.1872074.
    PubMed    


  84. WANG J, de Lima M, Cooper BW, Boughan K, et al
    Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jan 18:1-13. doi: 10.1080/10428194.2020.1864350.
    PubMed     Abstract available


  85. GARCIA-HORTON A, Maze D, McNamara CJ, Sibai H, et al
    Azacitidine and venetoclax for the treatment of accelerated and blast phase myeloproliferative neoplasms and chronic myelomonocytic leukemia: a case series.
    Leuk Lymphoma. 2021 Jan 15:1-6. doi: 10.1080/10428194.2020.1869961.
    PubMed    


  86. LI SY, Lu Y, Liu HC, Gang EJ, et al
    Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2021 Jan 13:1-6. doi: 10.1080/10428194.2020.1856832.
    PubMed    


  87. GHIA P, Dlugosz-Danecka M, Scarfo L, Jurczak W, et al
    Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jan 11:1-18. doi: 10.1080/10428194.2020.1864352.
    PubMed     Abstract available


  88. HAMPEL PJ, Parikh SA, Call TG
    Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2021 Jan 7:1-22. doi: 10.1080/10428194.2020.1869966.
    PubMed     Abstract available


  89. AMMATUNA E, van Doesum J
    Acute promyelocytic leukemia: if you wait it is too late.
    Leuk Lymphoma. 2021 Jan 6:1-2. doi: 10.1080/10428194.2020.1869227.
    PubMed    


  90. MIDDEKE JM, Teipel R, Rollig C, Stasik S, et al
    Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis.
    Leuk Lymphoma. 2021 Jan 5:1-15. doi: 10.1080/10428194.2020.1864354.
    PubMed     Abstract available


  91. HEATLEY SL, Asari K, Schutz CE, Leclercq TM, et al
    In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy.
    Leuk Lymphoma. 2021 Jan 2:1-13. doi: 10.1080/10428194.2020.1861275.
    PubMed     Abstract available


    December 2020
  92. ABBOTT D, Cherry E, Amaya M, McMahon C, et al
    The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 30:1-9. doi: 10.1080/10428194.2020.1864358.
    PubMed     Abstract available


  93. CARBONELL D, Suarez-Gonzalez J, Chicano M, Andres-Zayas C, et al
    Genetic biomarkers identify a subgroup of high-risk patients within low-risk NPM1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 29:1-12. doi: 10.1080/10428194.2020.1863400.
    PubMed     Abstract available


  94. HUANG J, Pan J, Sun X, Wang R, et al
    Changes in nutritional status and serum proteins in children with acute lymphoblastic leukemia during induction therapy: a single-centre report from China.
    Leuk Lymphoma. 2020 Dec 28:1-6. doi: 10.1080/10428194.2020.1864361.
    PubMed    


  95. HOLKOVA B, Shafer D, Yazbeck V, Dave S, et al
    Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2020 Dec 28:1-14. doi: 10.1080/10428194.2020.1861270.
    PubMed     Abstract available


  96. FOLTA A, Jurcek T, Kubesova B, Zackova D, et al
    Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients.
    Leuk Lymphoma. 2020 Dec 25:1-4. doi: 10.1080/10428194.2020.1861274.
    PubMed    


  97. CHEN X, Othus M, Wood BL, Walter RB, et al
    Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 19:1-7. doi: 10.1080/10428194.2020.1861267.
    PubMed     Abstract available


  98. MENDOZA H, Chen PH, Pine AB, Siddon AJ, et al
    A case of acute myeloid leukemia with unusual germline CEBPA mutation: lessons learned about mutation detection, location, and penetrance.
    Leuk Lymphoma. 2020 Dec 19:1-4. doi: 10.1080/10428194.2020.1861276.
    PubMed    


  99. PATEL AB, Deininger MW
    Genetic complexity of chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2020 Dec 18:1-22. doi: 10.1080/10428194.2020.1856837.
    PubMed     Abstract available


  100. ZHAO J, Bewersdorf JP, Jaszczur S, Kowalski A, et al
    High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis.
    Leuk Lymphoma. 2020 Dec 16:1-13. doi: 10.1080/10428194.2020.1856835.
    PubMed     Abstract available


  101. WEIL C, Chodick G, Shalev V, Kan I, et al
    Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel.
    Leuk Lymphoma. 2020 Dec 11:1-14. doi: 10.1080/10428194.2020.1858293.
    PubMed     Abstract available


  102. NING L, Li D, Lu P, Que Y, et al
    Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Dec 10:1-8. doi: 10.1080/10428194.2020.1855339.
    PubMed     Abstract available


  103. BARRIENTOS JC, Hillmen P, Salles G, Sharman J, et al
    No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib.
    Leuk Lymphoma. 2020 Dec 10:1-9. doi: 10.1080/10428194.2020.1845339.
    PubMed     Abstract available


  104. CUMBO C, Orsini P, Anelli L, Zagaria A, et al
    Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Dec 8:1-10. doi: 10.1080/10428194.2020.1856838.
    PubMed     Abstract available


  105. TERAO T, Ashimine H, Tsuyama N, Ikeda D, et al
    Development of BCR-ABL1-positive delta T-cell leukemia after treatment for thymoma type B1.
    Leuk Lymphoma. 2020 Dec 7:1-6. doi: 10.1080/10428194.2020.1856834.
    PubMed    


  106. ASSI R, Kantarjian H, Keating M, Pemmaraju N, et al
    Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
    Leuk Lymphoma. 2020 Dec 7:1-14. doi: 10.1080/10428194.2020.1849672.
    PubMed     Abstract available


  107. CHOW EJ, Doody DR, Wilkes JJ, Becker LK, et al
    Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees.
    Leuk Lymphoma. 2020 Dec 7:1-15. doi: 10.1080/10428194.2020.1855340.
    PubMed     Abstract available


  108. FOX TA, Carpenter B, Taj M, Perisoglou M, et al
    Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Dec 4:1-6. doi: 10.1080/10428194.2020.1855346.
    PubMed    


  109. DUNN KA, Connors J, Bielawski JP, Nearing JT, et al
    Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Dec 1:1-15. doi: 10.1080/10428194.2020.1850718.
    PubMed     Abstract available


  110. WEST ZE, Castellino SM, Monroe C, Thomas AS, et al
    Quantifying the difference in risk of adverse events by induction treatment regimen in pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Dec 1:1-14. doi: 10.1080/10428194.2020.1852471.
    PubMed     Abstract available


  111. CHAEKAL OK, van Besien K
    Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?
    Leuk Lymphoma. 2020;61:2783-2784.
    PubMed    


  112. KISHTAGARI A, Sekeres MA
    Eat and be healthy: nutritional status in myelodysplastic syndromes.
    Leuk Lymphoma. 2020;61:2788-2789.
    PubMed    


  113. SAMMARTANO V, Santoni A, Frediani B, Sicuranza A, et al
    Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant).
    Leuk Lymphoma. 2020;61:3523-3525.
    PubMed    


  114. MACKENZIE S, Gill S
    Long-term outcomes in patients with AML achieving first complete remission: confronting the double-hit of survivorship.
    Leuk Lymphoma. 2020;61:3035-3037.
    PubMed    


    November 2020
  115. SHARMAN JP, Burke JM, Yimer HA, Boxer MA, et al
    Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Nov 26:1-13. doi: 10.1080/10428194.2020.1850719.
    PubMed     Abstract available


  116. LEMIEUX-SARRASIN D, Pelland-Marcotte MC, Simonyan D, Martineau E, et al
    Distance to the pediatric oncology center does not affect survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Leuk Lymphoma. 2020 Nov 24:1-11. doi: 10.1080/10428194.2020.1849673.
    PubMed     Abstract available


  117. RASOR B, Dickerson T, Zhao Q, Elder P, et al
    Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS.
    Leuk Lymphoma. 2020 Nov 24:1-10. doi: 10.1080/10428194.2020.1849677.
    PubMed     Abstract available


  118. GREEN K, Tandon S, Ahmed M, Toscano W, et al
    Congenital acute myeloid leukemia: challenges and lessons. A 15-year experience from the UK.
    Leuk Lymphoma. 2020 Nov 23:1-8. doi: 10.1080/10428194.2020.1845335.
    PubMed     Abstract available


  119. WANG Z, Guan W, Wang M, Chen J, et al
    AML1-ETO inhibits acute myeloid leukemia immune escape by CD48.
    Leuk Lymphoma. 2020 Nov 21:1-10. doi: 10.1080/10428194.2020.1849680.
    PubMed     Abstract available


  120. KHOUNTHAM S, Shindiapina P, Mo X, Lachowiez C, et al
    Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Nov 19:1-6. doi: 10.1080/10428194.2020.1838508.
    PubMed    


  121. WANG T, Zhou B, Zhang J, Zhang X, et al
    Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation.
    Leuk Lymphoma. 2020 Nov 16:1-4. doi: 10.1080/10428194.2020.1846736.
    PubMed     Abstract available


  122. FU W, Huang A, Lu G, Ni X, et al
    Value of pre-transplant consolidation chemotherapy in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation without minimal residual disease in first complete remission.
    Leuk Lymphoma. 2020 Nov 11:1-8. doi: 10.1080/10428194.2020.1845340.
    PubMed     Abstract available


  123. MESSORI A, Bartoli L
    Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.
    Leuk Lymphoma. 2020 Nov 9:1. doi: 10.1080/10428194.2020.1845337.
    PubMed    


  124. COUTURIER MA, Thomas X, Raffoux E, Huguet F, et al
    Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1844198.
    PubMed     Abstract available


  125. OTTMANN OG, Stegelmann F, Breccia M, Steegmann JL, et al
    Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study.
    Leuk Lymphoma. 2020 Nov 6:1-4. doi: 10.1080/10428194.2020.1839649.
    PubMed    


  126. EFFICACE F, Iurlo A, Patriarca A, Stagno F, et al
    Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1838509.
    PubMed     Abstract available


  127. TROMP VNMF, Timmers L, Koningen L, Janssen JJWM, et al
    Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.
    Leuk Lymphoma. 2020 Nov 6:1-10. doi: 10.1080/10428194.2020.1839655.
    PubMed     Abstract available


  128. LUNGHI M, Patriarca A, Greco M, Taherinasab A, et al
    Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Nov 5:1-3. doi: 10.1080/10428194.2020.1842401.
    PubMed    


  129. SHI D, Li Z, Li Y, Jiang Q, et al
    Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2020 Nov 5:1-9. doi: 10.1080/10428194.2020.1842397.
    PubMed     Abstract available


  130. BUSCHNER G, Feuerecker B, Spinner S, Seidl C, et al
    Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces (18)F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosis.
    Leuk Lymphoma. 2020 Nov 3:1-10. doi: 10.1080/10428194.2020.1839648.
    PubMed     Abstract available


  131. GAUT D, Mead M
    Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies.
    Leuk Lymphoma. 2020 Nov 2:1-24. doi: 10.1080/10428194.2020.1827251.
    PubMed     Abstract available


  132. MEGIAS-VERICAT JE, Martinez-Cuadron D, Herrero MJ, Rodriguez-Veiga R, et al
    Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2020 Nov 2:1-10. doi: 10.1080/10428194.2020.1839650.
    PubMed     Abstract available


  133. KEBRIAEI P
    Toward a cure in relapsed ALL: we must do better.
    Leuk Lymphoma. 2020;61:2544-2545.
    PubMed    


  134. PAN W, Zhao X, Shi W, Jiang Z, et al
    Venetoclax induced complete remission in extramedullary relapse of AML co-harboring NPM1, TET2, and NRAS mutations after haploidentical hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2020;61:2756-2759.
    PubMed    


    October 2020
  135. LEBLANC TW
    Improving end-of-life care for patients with leukemia: is inpatient death the right measure?
    Leuk Lymphoma. 2020 Oct 29:1-3. doi: 10.1080/10428194.2020.1838510.
    PubMed    


  136. VAKRMANOVA B, Fronkova E, Zuna J, Janotova I, et al
    Blast clearance after one week of corticosteroids correlates with outcome and genetics but does not justify adding a residual disease time point in acute lymphoblastic leukemia treatment.
    Leuk Lymphoma. 2020 Oct 29:1-3. doi: 10.1080/10428194.2020.1839659.
    PubMed    


  137. BARSOUM B, Henneman A, Ahmad S, Ghiuzeli C, et al
    Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Oct 27:1-6. doi: 10.1080/10428194.2020.1837797.
    PubMed     Abstract available


  138. KARIGANE D, Kasahara H, Shiroshita K, Fujita S, et al
    Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow stem/progenitors.
    Leuk Lymphoma. 2020 Oct 26:1-9. doi: 10.1080/10428194.2020.1837366.
    PubMed     Abstract available


  139. FREYER CW, Peterson CE, Man Y, Przespolewski A, et al
    Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Oct 26:1-7. doi: 10.1080/10428194.2020.1838507.
    PubMed     Abstract available


  140. RODGERS TD, Williams AM, Baran A, Reagan PM, et al
    Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2020 Oct 25:1-8. doi: 10.1080/10428194.2020.1837796.
    PubMed     Abstract available


  141. PETERLIN P, Chevallier P, Knapper S, Collin M, et al
    FLT3 ligand in acute myeloid leukemia: a simple test with deep implications.
    Leuk Lymphoma. 2020 Oct 20:1-7. doi: 10.1080/10428194.2020.1834091.
    PubMed     Abstract available


  142. NORRIS EJ, Patel YC, Klotz KE, Steuerwald N, et al
    Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines.
    Leuk Lymphoma. 2020 Oct 16:1-5. doi: 10.1080/10428194.2020.1827245.
    PubMed    


  143. LU J, Wu X, Wang L, Li T, et al
    Long noncoding RNA LINC00467 facilitates the progression of acute myeloid leukemia by targeting the miR-339/SKI pathway.
    Leuk Lymphoma. 2020 Oct 15:1-10. doi: 10.1080/10428194.2020.1832667.
    PubMed     Abstract available


  144. CUI L, Gao C, Wang CJ, Zhao XX, et al
    Combined analysis of IKZF1 deletions and CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Oct 15:1-9. doi: 10.1080/10428194.2020.1832668.
    PubMed     Abstract available


  145. O'BRIEN G, Zyla J, Manola KN, Pagoni MN, et al
    Identification of two novel mutations in human acute myeloid leukemia cases.
    Leuk Lymphoma. 2020 Oct 14:1-8. doi: 10.1080/10428194.2020.1832664.
    PubMed     Abstract available


  146. LOH JBE, Walker P, Avery S, Patil S, et al
    Double trouble or a silver lining? A case report of two patients with NPM1-mutated donor-derived acute myeloid leukemia (AML).
    Leuk Lymphoma. 2020 Oct 13:1-3. doi: 10.1080/10428194.2020.1832663.
    PubMed    


  147. WILLEKENS C, Rahme R, Duchmann M, Vidal V, et al
    Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.
    Leuk Lymphoma. 2020 Oct 12:1-8. doi: 10.1080/10428194.2020.1832661.
    PubMed     Abstract available


  148. LOH KP, Abdallah M, Kadambi S, Wells M, et al
    Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.
    Leuk Lymphoma. 2020 Oct 11:1-12. doi: 10.1080/10428194.2020.1832662.
    PubMed     Abstract available


  149. HEINICKE T, Labopin M, Polge E, Stelljes M, et al
    Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
    Leuk Lymphoma. 2020 Oct 11:1-11. doi: 10.1080/10428194.2020.1827248.
    PubMed     Abstract available


  150. ZACKOVA D, Klamova H, Belohlavkova P, Stejskal L, et al
    Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
    Leuk Lymphoma. 2020 Oct 6:1-9. doi: 10.1080/10428194.2020.1827242.
    PubMed     Abstract available


  151. ANDERSON MA, Seymour JF
    Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?
    Leuk Lymphoma. 2020;61:2286-2288.
    PubMed    


  152. REYNOLDS G, Slavin M, Teh BW
    Ibrutinib and invasive fungal infections: the known, the unknown and the known unknowns.
    Leuk Lymphoma. 2020;61:2292-2294.
    PubMed    


    September 2020
  153. SILVEIRA DRA, Coelho-Silva JL, Silva WF, Vallance G, et al
    A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?
    Leuk Lymphoma. 2020 Sep 30:1-11. doi: 10.1080/10428194.2020.1827252.
    PubMed     Abstract available


  154. ZHOU D, Xu P, Zhou X, Diao Z, et al
    MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation.
    Leuk Lymphoma. 2020 Sep 30:1-11. doi: 10.1080/10428194.2020.1824067.
    PubMed     Abstract available


  155. XIE J, Nachabe A, Hathaway LJ, Farah B, et al
    The prognostic implications of tetraploidy/near-Tetraploidy in acute myeloid leukemia: a case series and systematic review of the literature.
    Leuk Lymphoma. 2020 Sep 29:1-8. doi: 10.1080/10428194.2020.1817435.
    PubMed     Abstract available


  156. DALEY RJ, Rajeeve S, Kabel CC, Pappacena JJ, et al
    Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Sep 26:1-9. doi: 10.1080/10428194.2020.1824068.
    PubMed     Abstract available


  157. CORTES JE, Candoni A, Clark RE, Leber B, et al
    Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review.
    Leuk Lymphoma. 2020 Sep 24:1-19. doi: 10.1080/10428194.2020.1817445.
    PubMed     Abstract available


  158. SHAH N, Rockwell B, Kazemi M, Peeke S, et al
    Ethnic disparities in survival of adult B-cell acute lymphoblastic leukemia in modern era - a SEER analysis.
    Leuk Lymphoma. 2020 Sep 22:1-4. doi: 10.1080/10428194.2020.1808211.
    PubMed    


  159. YILMAZ M, Kantarjian HM, Toruner G, Yin CC, et al
    Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis.
    Leuk Lymphoma. 2020 Sep 21:1-5. doi: 10.1080/10428194.2020.1824071.
    PubMed     Abstract available


  160. MUSHTAQ MU, Harrington AM, Chaudhary SG, Michaelis LC, et al
    Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 Sep 19:1-9. doi: 10.1080/10428194.2020.1821009.
    PubMed     Abstract available


  161. HALPERN AB, Othus M, Howard NP, Hendrie PC, et al
    Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2020 Sep 13:1-5. doi: 10.1080/10428194.2020.1821008.
    PubMed    


  162. AVGERINOU G, Katsibardi Kappa, Filippidou M, Tzanoudaki M, et al
    Cytogenetically cryptic and fish negative PML/RARA rearrangement in acute promyelocytic leukemia detected by RT-PCR.
    Leuk Lymphoma. 2020 Sep 10:1-3. doi: 10.1080/10428194.2020.1808202.
    PubMed    


  163. DAO FT, Chen WM, Long LY, Li LD, et al
    High PRDM16 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk: a comprehensive cohort study from a single Chinese center.
    Leuk Lymphoma. 2020 Sep 9:1-9. doi: 10.1080/10428194.2020.1817436.
    PubMed     Abstract available


  164. HANDUNNETTI SM, Tam CS
    Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
    Leuk Lymphoma. 2020 Sep 8:1-3. doi: 10.1080/10428194.2020.1811865.
    PubMed    


  165. YOST CM, Gaikwad AS, Parsons DW, Rabin KR, et al
    Aberrant leukemia-associated immunophenotype as potential harbinger of lineage switch in KMT2A-rearranged leukemia: a case series.
    Leuk Lymphoma. 2020 Sep 2:1-4. doi: 10.1080/10428194.2020.1815018.
    PubMed    


    August 2020
  166. MOHAMMAD IS, Lin K, Oates M, Khan UT, et al
    Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Aug 28:1-13. doi: 10.1080/10428194.2020.1811274.
    PubMed     Abstract available


  167. ZHOU X, Ma X, Sun H, Li X, et al
    Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.
    Leuk Lymphoma. 2020 Aug 28:1-9. doi: 10.1080/10428194.2020.1811269.
    PubMed     Abstract available


  168. ARUNACHALAM AK, Janet NB, Korula A, Lakshmi KM, et al
    Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 27:1-8. doi: 10.1080/10428194.2020.1811272.
    PubMed     Abstract available


  169. SINGH A, Motilal Nehru V, Peace D
    Refractory acquired angioedema in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Aug 25:1-2. doi: 10.1080/10428194.2020.1804559.
    PubMed    


  170. ROBERTS KE, Deininger MW, Hildebrandt GC, Gackenbach BK, et al
    Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 24:1-4. doi: 10.1080/10428194.2020.1808210.
    PubMed    


  171. ROBOZ GJ, Strickland SA, Litzow MR, Dalovisio A, et al
    Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.
    Leuk Lymphoma. 2020 Aug 19:1-8. doi: 10.1080/10428194.2020.1805109.
    PubMed     Abstract available


  172. NAGAHATA Y, Kondo T, Ono Y, Hiramoto N, et al
    High-dose cytarabine chemotherapy (>/=4 g/m(2)/day) before allogeneic hematopoietic stem cell transplantation for non-core-binding-factor AML in the first complete remission.
    Leuk Lymphoma. 2020 Aug 17:1-9. doi: 10.1080/10428194.2020.1805112.
    PubMed     Abstract available


  173. SCALZULLI E, Colafigli G, Pepe S, De Luca G, et al
    Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.
    Leuk Lymphoma. 2020 Aug 16:1-2. doi: 10.1080/10428194.2020.1808205.
    PubMed    


  174. TRANG E, Ngo D, Chen J, Aldoss I, et al
    Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 13:1-4. doi: 10.1080/10428194.2020.1805108.
    PubMed     Abstract available


  175. LIU X, Zou Y, Chen X, Wang S, et al
    Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Aug 11:1-8. doi: 10.1080/10428194.2020.1805739.
    PubMed     Abstract available


  176. ANDREWS C, Lam W, Sibai H
    The successful use of FLT3 inhibitors in FLT3-positive mixed phenotype acute leukemia.
    Leuk Lymphoma. 2020 Aug 6:1-3. doi: 10.1080/10428194.2020.1802451.
    PubMed    


  177. FRASER GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, et al
    Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2020 Aug 6:1-10. doi: 10.1080/10428194.2020.1795159.
    PubMed     Abstract available


  178. SHAIKH AF, Kakirde C, Dhamne C, Bhanshe P, et al
    Machine learning derived genomics driven prognostication for acute myeloid leukemia with RUNX1-RUNX1T1.
    Leuk Lymphoma. 2020 Aug 5:1-7. doi: 10.1080/10428194.2020.1798951.
    PubMed     Abstract available


  179. MAJOR CK, Kantarjian H, Sasaki K, Borthakur G, et al
    Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.
    Leuk Lymphoma. 2020 Aug 5:1-8. doi: 10.1080/10428194.2020.1802450.
    PubMed     Abstract available


  180. OBIORAH IE, Francischetti IMB, Wang HW, Ahn IE, et al
    Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.
    Leuk Lymphoma. 2020 Aug 5:1-11. doi: 10.1080/10428194.2020.1797007.
    PubMed     Abstract available


    July 2020
  181. JANN JC, Streuer A, Hecht A, Nolte F, et al
    RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events.
    Leuk Lymphoma. 2020 Jul 29:1-12. doi: 10.1080/10428194.2020.1797006.
    PubMed     Abstract available


  182. MENDES-DE-ALMEIDA DP, Sellos F, Moura PG, Dos Santos-Bueno FV, et al
    Acute myeloid leukemia associated with a novel GATA2 mutation: a case report and the importance to identify GATA2 haplodeficiency.
    Leuk Lymphoma. 2020 Jul 27:1-4. doi: 10.1080/10428194.2020.1795163.
    PubMed    


  183. SCHULZ WL, Rinder HM, Durant TJS, Tormey CA, et al
    Impact of intra-tumoral heterogeneity detected by next-generation sequencing on acute myeloid leukemia survival.
    Leuk Lymphoma. 2020 Jul 26:1-3. doi: 10.1080/10428194.2020.1797016.
    PubMed    


  184. VALLATHOL DH, Ali AZ, Alapati N, Manasa N, et al
    Lutetium 177 dotatate induced acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jul 25:1-3. doi: 10.1080/10428194.2020.1795158.
    PubMed    


  185. CHEN Z, Hu S, Wang SA, Konopleva M, et al
    Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 23:1-8. doi: 10.1080/10428194.2020.1795160.
    PubMed     Abstract available


  186. THAKRAL B, Daver N, Tang Z, Patel KP, et al
    Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.
    Leuk Lymphoma. 2020 Jul 22:1-4. doi: 10.1080/10428194.2020.1797008.
    PubMed    


  187. BARTHEL R, Fedorchenko O, Velmans T, Rosen N, et al
    CD74 is dispensable for development of chronic lymphocytic leukemia in Emicro-TCL1 transgenic mice.
    Leuk Lymphoma. 2020 Jul 15:1-12. doi: 10.1080/10428194.2020.1791851.
    PubMed     Abstract available


  188. HU B, Lin X, Lee HC, Huang X, et al
    Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.
    Leuk Lymphoma. 2020 Jul 14:1-10. doi: 10.1080/10428194.2020.1783444.
    PubMed     Abstract available



  189. Detection and clinical significance of gene rearrangements in Chinese patients with adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 14:1. doi: 10.1080/10428194.2020.1794540.
    PubMed    


  190. NESR G, Laffan M, Claudiani S, Innes A, et al
    Platelet function in patients with chronic myeloid leukemia treated with asciminib.
    Leuk Lymphoma. 2020 Jul 12:1-3. doi: 10.1080/10428194.2020.1791856.
    PubMed    


  191. ALOTAIBI AS, Abdulrazzaq M, Patel KP, Ravandi F, et al
    Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791853.
    PubMed    


  192. SAKURAI A, Nakazato T
    The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791847.
    PubMed    


  193. PANDEY RK, DiPippo A, Kadia T, Pemmaraju N, et al
    Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 11:1-3. doi: 10.1080/10428194.2020.1791852.
    PubMed    


  194. ZHAO X, Lu X, Tang L, Yan H, et al
    Comparing the outcomes between TMLI and non-TMLI conditioning regimens for adult high-risk acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Leuk Lymphoma. 2020 Jul 10:1-9. doi: 10.1080/10428194.2020.1789621.
    PubMed     Abstract available


  195. ALI N, Tomlinson B, Metheny L, Goldstein SC, et al
    Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jul 10:1-11. doi: 10.1080/10428194.2020.1789630.
    PubMed     Abstract available


  196. LIU K, Chu J, Dai Y, Jiang A, et al
    Long-term follow-up of acute lymphoblastic leukemia in young children treated by the SCMC-ALL-2009 protocol.
    Leuk Lymphoma. 2020 Jul 9:1-9. doi: 10.1080/10428194.2020.1786557.
    PubMed     Abstract available


  197. GODWIN CD, Bates OM, Jean SR, Laszlo GS, et al
    Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia.
    Leuk Lymphoma. 2020 Jul 4:1-5. doi: 10.1080/10428194.2020.1786553.
    PubMed    


  198. GOKBUGET N, Zugmaier G, Dombret H, Stein A, et al
    Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 3:1-9. doi: 10.1080/10428194.2020.1780583.
    PubMed     Abstract available


  199. DE CASTRO CG JR, Gregianin LJ, Burger JA
    Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.
    Leuk Lymphoma. 2020 Jul 1:1-2. doi: 10.1080/10428194.2020.1786559.
    PubMed    


  200. MULLIKIN D, Ranch D, Khalfe Y, Lucari B, et al
    Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 Jul 1:1-4. doi: 10.1080/10428194.2020.1783445.
    PubMed    


  201. ZHANG Z, Zhang R, Qi J, Miao W, et al
    The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2020 Jul 1:1-10. doi: 10.1080/10428194.2020.1780587.
    PubMed     Abstract available


  202. HSU J, Van Besien K, Baron F
    Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation?
    Leuk Lymphoma. 2020;61:1529-1534.
    PubMed    


    June 2020
  203. SHIMONY S, Rozovski U, Sudry N, Yeshurun M, et al
    Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment.
    Leuk Lymphoma. 2020 Jun 24:1-6. doi: 10.1080/10428194.2020.1779253.
    PubMed     Abstract available


  204. COTE-OLIJNYK M, Fowlkes S, Assouline S
    Chronic myelogenous leukemia presenting as central retinal vein occlusion.
    Leuk Lymphoma. 2020 Jun 22:1-4. doi: 10.1080/10428194.2020.1775203.
    PubMed    


  205. SHOAG JM, Barredo JC, Lossos IS, Pinheiro PS, et al
    Acute lymphoblastic leukemia mortality in Hispanic Americans.
    Leuk Lymphoma. 2020 Jun 22:1-8. doi: 10.1080/10428194.2020.1779260.
    PubMed     Abstract available


  206. MOHYUDDIN GR, Abbasi S, Ripp J, Singh A, et al
    Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better.
    Leuk Lymphoma. 2020 Jun 18:1-3. doi: 10.1080/10428194.2020.1780585.
    PubMed    


  207. MOLICA S, Lentini M, Zappala D, Levato L, et al
    Effects of ibrutinib on glucose-lipid metabolism in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2020 Jun 16:1-3. doi: 10.1080/10428194.2020.1779258.
    PubMed    


  208. LU JP, Wang FX, Wen SP, Liu X, et al
    Haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in the treatment of T-lymphoblastic lymphoma.
    Leuk Lymphoma. 2020 Jun 16:1-4. doi: 10.1080/10428194.2020.1775205.
    PubMed    


  209. LI AY, Kashanian SM, Hambley BC, Zacholski K, et al
    Clustered incidence of adult acute promyelocytic leukemia in the vicinity of Baltimore.
    Leuk Lymphoma. 2020 Jun 14:1-5. doi: 10.1080/10428194.2020.1775209.
    PubMed    


  210. RASHED RA, Hassan NM, Hussein MM
    MicroRNA-92a as a marker of treatment response and survival in adult acute myeloid leukemia patients.
    Leuk Lymphoma. 2020 Jun 14:1-7. doi: 10.1080/10428194.2020.1775218.
    PubMed     Abstract available


  211. FREI M, Aitken SL, Jain N, Thompson P, et al
    Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib.
    Leuk Lymphoma. 2020 Jun 12:1-4. doi: 10.1080/10428194.2020.1775215.
    PubMed    


  212. TAVITIAN S, Uzunov M, Berard E, Bouscary D, et al
    Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study.
    Leuk Lymphoma. 2020 Jun 8:1-7. doi: 10.1080/10428194.2020.1762876.
    PubMed     Abstract available


  213. PAGANI IS, Dang P, Saunders VA, Braley J, et al
    Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia.
    Leuk Lymphoma. 2020 Jun 6:1-3. doi: 10.1080/10428194.2020.1772476.
    PubMed    


  214. PLEYER C, Sun C, Desai S, Ahn IE, et al
    Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
    Leuk Lymphoma. 2020 Jun 6:1-8. doi: 10.1080/10428194.2020.1772477.
    PubMed     Abstract available


  215. CHEN QC, Chen YH
    Mutational profiling of myeloid neoplasms, focusing on AML with myelodysplasia-related changes (MRC) in comparison with MDS and AML without MRC.
    Leuk Lymphoma. 2020;61:1269-1271.
    PubMed    


  216. TADMOR T, Greenfeld S
    Incidence and diagnosis of Richter transformation: transition from the era of chemoimmunotherapy to novel targeted agents.
    Leuk Lymphoma. 2020;61:1272-1274.
    PubMed    


  217. MATUTES E, Polliack A
    The challenge of unavailable IGH mutational status in CLL in resource-limited settings.
    Leuk Lymphoma. 2020;61:1275-1276.
    PubMed    


    May 2020
  218. STRICKLAND SA, Wang XV, Cerny J, Rowe JM, et al
    A novel PrECOG (PrE0901) dose-escalation trial using eltrombopag: enhanced platelet recovery during consolidation therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 30:1-9. doi: 10.1080/10428194.2020.1762878.
    PubMed     Abstract available


  219. NIE L, Ma R, Yuan X, Jiang L, et al
    The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 May 30:1-6. doi: 10.1080/10428194.2020.1768386.
    PubMed     Abstract available


  220. COHEN J, Palumbo A, Wing J, Heinrich MC, et al
    Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes.
    Leuk Lymphoma. 2020 May 26:1-4. doi: 10.1080/10428194.2020.1768380.
    PubMed    


  221. KOEHLER AB, Leung N, Call TG, Rabe KG, et al
    Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
    Leuk Lymphoma. 2020 May 25:1-6. doi: 10.1080/10428194.2020.1768384.
    PubMed     Abstract available


  222. BRUZZESE A, Chistolini A, Morano SG, Fegatelli DA, et al
    Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal.
    Leuk Lymphoma. 2020 May 21:1-3. doi: 10.1080/10428194.2020.1762880.
    PubMed    


  223. WANG ES, Aplenc R, Chirnomas D, Dugan M, et al
    Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 20:1-9. doi: 10.1080/10428194.2020.1742897.
    PubMed     Abstract available


  224. KNEZ V, Bao L, Carstens B, Liang X, et al
    Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood.
    Leuk Lymphoma. 2020 May 19:1-7. doi: 10.1080/10428194.2020.1761970.
    PubMed     Abstract available


  225. FULCHER J, Leung E, Christou G, Bredeson C, et al
    Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 May 19:1-3. doi: 10.1080/10428194.2020.1761965.
    PubMed    


  226. PETTERSSON L, Chen Y, George AM, Rigo R, et al
    Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis.
    Leuk Lymphoma. 2020 May 19:1-12. doi: 10.1080/10428194.2020.1755855.
    PubMed     Abstract available


  227. BEWERSDORF JP, Zeidan AM
    Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
    Leuk Lymphoma. 2020 May 18:1-18. doi: 10.1080/10428194.2020.1761968.
    PubMed     Abstract available


  228. GAULIN C, Chan A, Derkach A, Park JH, et al
    Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2020 May 18:1-5. doi: 10.1080/10428194.2020.1765236.
    PubMed    


  229. PAPANOTA AM, Ntanasis-Stathopoulos I, Liakea A, Kastritis E, et al
    Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis.
    Leuk Lymphoma. 2020 May 13:1-4. doi: 10.1080/10428194.2020.1761969.
    PubMed    


  230. JABBOUR E, Stelljes M, Advani AS, DeAngelo DJ, et al
    Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
    Leuk Lymphoma. 2020 May 7:1-4. doi: 10.1080/10428194.2020.1751839.
    PubMed    


  231. HAN H, Shin DY, Kim D, Kim H, et al
    Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 6:1-11. doi: 10.1080/10428194.2020.1747062.
    PubMed     Abstract available


  232. LUSKIN MR, Kim AS, Patel SS, Wright K, et al
    Evidence for separate transformation to acute myeloid leukemia and blastic plamacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone.
    Leuk Lymphoma. 2020 May 4:1-4. doi: 10.1080/10428194.2020.1755856.
    PubMed    


  233. TODISCO E, Gigli F, Sammassimo S, Camisaschi C, et al
    Efficacy of venetoclax based salvage chemotherapy followed by "Minimal Residual Disease driven"-venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia.
    Leuk Lymphoma. 2020 May 2:1-3. doi: 10.1080/10428194.2020.1759049.
    PubMed    


  234. BEWERSDORF JP, Shallis RM, Gowda L, Wei W, et al
    Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.
    Leuk Lymphoma. 2020 May 2:1-11. doi: 10.1080/10428194.2020.1759051.
    PubMed     Abstract available


    April 2020
  235. BEWERSDORF JP, Shallis RM, Diadamo A, Gowda L, et al
    Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?
    Leuk Lymphoma. 2020 Apr 26:1-4. doi: 10.1080/10428194.2020.1755858.
    PubMed    


  236. RINGELSTEIN-HARLEV S
    Immune dysfunction complexity in chronic lymphocytic leukemia an issue to consider when designing novel therapeutic strategies.
    Leuk Lymphoma. 2020 Apr 26:1-9. doi: 10.1080/10428194.2020.1755857.
    PubMed     Abstract available


  237. THOMPSON ER, Lim KJC, Kuzich JA, McBean M, et al
    Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia.
    Leuk Lymphoma. 2020 Apr 22:1-3. doi: 10.1080/10428194.2020.1753045.
    PubMed    


  238. STAHL M, Tallman MS
    Late and very late relapses in acute myeloid leukemia (AML).
    Leuk Lymphoma. 2020 Apr 14:1-2. doi: 10.1080/10428194.2020.1745204.
    PubMed    


  239. RAMALINGAM TR, Muthu A, Vaidhyanathan L, Ramakrishnan B, et al
    Immunophenotypic modulation in pediatric B lymphoblastic leukemia and its implications in MRD detection.
    Leuk Lymphoma. 2020 Apr 12:1-7. doi: 10.1080/10428194.2020.1742902.
    PubMed     Abstract available


  240. ZHANG Y, Xiao L
    Identification and validation of a prognostic 8-gene signature for acute myeloid leukemia.
    Leuk Lymphoma. 2020 Apr 8:1-8. doi: 10.1080/10428194.2020.1742898.
    PubMed     Abstract available


  241. GARCIA-MANERO G, Pemmaraju N, Alvarado Y, Naqvi K, et al
    Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes.
    Leuk Lymphoma. 2020 Apr 7:1-11. doi: 10.1080/10428194.2020.1747065.
    PubMed     Abstract available


    March 2020
  242. CAI P, Wu Q, Wang Y, Yang X, et al
    An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia.
    Leuk Lymphoma. 2020 Mar 31:1-7. doi: 10.1080/10428194.2020.1742910.
    PubMed     Abstract available


  243. DUCOURNEAU B, Fenwarth L, Duployez N, Lambert J, et al
    Cytogenetically masked CBFB-MYH11 fusion and concomitant TP53 deletion in a case of acute myeloid leukemia with a complex karyotype.
    Leuk Lymphoma. 2020 Mar 29:1-3. doi: 10.1080/10428194.2020.1742905.
    PubMed    


  244. OTOUKESH S, Zhang J, Nakamura R, Stein AS, et al
    The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement.
    Leuk Lymphoma. 2020 Mar 19:1-4. doi: 10.1080/10428194.2020.1742908.
    PubMed    


  245. GUOLO F, Minetto P, Clavio M, Marcolin R, et al
    Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
    Leuk Lymphoma. 2020 Mar 18:1-7. doi: 10.1080/10428194.2020.1737685.
    PubMed     Abstract available


  246. MEACHAM PJ, Williams AM, Strawderman M, Baran AM, et al
    Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
    Leuk Lymphoma. 2020 Mar 16:1-9. doi: 10.1080/10428194.2020.1737690.
    PubMed     Abstract available


  247. TAKAOKA K, Koya J, Yoshimi A, Toya T, et al
    Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study.
    Leuk Lymphoma. 2020 Mar 11:1-7. doi: 10.1080/10428194.2020.1734595.
    PubMed     Abstract available


  248. DHAKAL P, Lyden E, Muir KE, Al-Kadhimi ZS, et al
    Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.
    Leuk Lymphoma. 2020 Mar 11:1-7. doi: 10.1080/10428194.2020.1737687.
    PubMed     Abstract available


  249. ASSOULINE S, Amrein L, Aloyz R, Banerji V, et al
    IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2020 Mar 10:1-7. doi: 10.1080/10428194.2020.1734594.
    PubMed     Abstract available


  250. WILLIAMS AM, van Wijngaarden E, Seplaki CL, Heckler CE, et al
    Cognitive function in patients with chronic lymphocytic leukemia: a cross-sectional study examining effects of disease and treatment.
    Leuk Lymphoma. 2020 Mar 9:1-9. doi: 10.1080/10428194.2020.1728748.
    PubMed     Abstract available


  251. DIMAGGIO E, Zhou JM, Caddell R, Tombleson R, et al
    Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.
    Leuk Lymphoma. 2020 Mar 5:1-10. doi: 10.1080/10428194.2020.1731498.
    PubMed     Abstract available


  252. TURHAN AG, Hugues P, Sorel N, Desterke C, et al
    Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML).
    Leuk Lymphoma. 2020 Mar 3:1-5. doi: 10.1080/10428194.2020.1734593.
    PubMed    


    February 2020
  253. SHAH SCHARFF BFS, Modvig S, Thastrup M, Levinsen M, et al
    A comprehensive clinical study of integrins in acute lymphoblastic leukemia indicates a role of alpha6/CD49f in persistent minimal residual disease and alpha5 in the colonization of cerebrospinal fluid.
    Leuk Lymphoma. 2020 Feb 28:1-5. doi: 10.1080/10428194.2020.1731500.
    PubMed    


  254. GROSICKI S, Lech-Maranda E, Govind Babu K, Rybka J, et al
    A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
    Leuk Lymphoma. 2020 Feb 28:1-4. doi: 10.1080/10428194.2020.1732960.
    PubMed    


  255. ROBOZ GJ, Larson ML, Rubenstein SE, Solomon SR, et al
    Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
    Leuk Lymphoma. 2020 Feb 26:1-7. doi: 10.1080/10428194.2020.1725503.
    PubMed     Abstract available


  256. SHALLIS RM, Stahl M, Wei W, Montesinos P, et al
    Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy.
    Leuk Lymphoma. 2020 Feb 26:1-6. doi: 10.1080/10428194.2020.1728753.
    PubMed    


  257. NGUYEN L, Zhang X, Roberts E, Yun S, et al
    Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated RUNX1 versus acute myeloid leukemia with myelodysplasia-related changes with mutated RUNX1.
    Leuk Lymphoma. 2020 Feb 24:1-11. doi: 10.1080/10428194.2020.1723016.
    PubMed     Abstract available


  258. PALMIERI R, Buckley SA, Othus M, Halpern AB, et al
    Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-g
    Leuk Lymphoma. 2020 Feb 20:1-4. doi: 10.1080/10428194.2020.1728754.
    PubMed    


  259. ZAHRAN AM, Moeen SM, Thabet AF, Rayan A, et al
    Monocytic myeloid-derived suppressor cells in chronic lymphocytic leukemia patients: a single center experience.
    Leuk Lymphoma. 2020 Feb 20:1-8. doi: 10.1080/10428194.2020.1728747.
    PubMed     Abstract available


  260. GALLEGO HERNANZ MP, Sorel N, Bouyer S, Desmier D, et al
    Longitudinal clonal architecture of acute myeloid leukemia with NPM1 driver insertion, early TET2 mutations and secondary e6a2 BCR-ABL1 rearrangement.
    Leuk Lymphoma. 2020 Feb 20:1-5. doi: 10.1080/10428194.2020.1728751.
    PubMed    


  261. LIVA SG, Coss CC, Wang J, Blum W, et al
    Phase I study of AR-42 and decitabine in acute myeloid leukemia.
    Leuk Lymphoma. 2020 Feb 8:1-9. doi: 10.1080/10428194.2020.1719095.
    PubMed     Abstract available


  262. ASGHARI H, Lancet J
    Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
    Leuk Lymphoma. 2020 Feb 8:1-8. doi: 10.1080/10428194.2020.1719093.
    PubMed     Abstract available


  263. HAZAR V, Karasu GT, Uygun V, Ozbek N, et al
    Role of a second transplantation for children with acute leukemia following posttransplantation relapse: a study by the Turkish Bone Marrow Transplantation Study Group.
    Leuk Lymphoma. 2020 Feb 8:1-10. doi: 10.1080/10428194.2020.1716220.
    PubMed     Abstract available


  264. CHIEN KS, Class CA, Montalban-Bravo G, Wei Y, et al
    LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
    Leuk Lymphoma. 2020 Feb 8:1-7. doi: 10.1080/10428194.2020.1723014.
    PubMed     Abstract available


  265. LACHOWIEZ C, DiNardo CD, Konopleva M
    Venetoclax in acute myeloid leukemia - current and future directions.
    Leuk Lymphoma. 2020 Feb 7:1-10. doi: 10.1080/10428194.2020.1719098.
    PubMed     Abstract available


  266. NTZIACHRISTOS P
    iAMPlified gene expression offers new insights in B cell precursor leukemia subtype.
    Leuk Lymphoma. 2020 Feb 3:1-3. doi: 10.1080/10428194.2019.1695055.
    PubMed    


  267. ANSELL SM
    Activation-induced T-cell exhaustion: too much of a good thing?
    Leuk Lymphoma. 2020;61:255-256.
    PubMed    


  268. DUPLOYEZ N, Fenwarth L
    Controversies about germline RUNX1 missense variants.
    Leuk Lymphoma. 2020;61:497-499.
    PubMed    


    January 2020
  269. WANG Q, Jiang C, Zhang Y, Zhang Y, et al
    Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis.
    Leuk Lymphoma. 2020 Jan 27:1-11. doi: 10.1080/10428194.2019.1711074.
    PubMed     Abstract available


  270. ICHIKAWA S, Fukuhara N, Saito K, Yokoyama H, et al
    Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
    Leuk Lymphoma. 2020 Jan 21:1-4. doi: 10.1080/10428194.2020.1713322.
    PubMed    


  271. SHAH S, Martin A, Turner M, Cong Z, et al
    A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease.
    Leuk Lymphoma. 2020 Jan 21:1-11. doi: 10.1080/10428194.2019.1709834.
    PubMed     Abstract available


  272. MARIANI S, Trisolini SM, Minotti C, Breccia M, et al
    Very late acute myeloid leukemia relapse: clinical features, treatment and outcome.
    Leuk Lymphoma. 2020 Jan 16:1-4. doi: 10.1080/10428194.2020.1713320.
    PubMed    


  273. RYLAND GL, Fox LC, Wootton V, Thompson ER, et al
    Severe chemotherapy toxicity in a 10-year-old with T-acute lymphoblastic lymphoma harboring biallelic FANCM variants.
    Leuk Lymphoma. 2020 Jan 16:1-3. doi: 10.1080/10428194.2019.1711075.
    PubMed    


  274. ANDREANI G, Camerlo S, Pautasso M, Dragani M, et al
    Phenotypical heterogeneity of acute myeloid leukemia in the elderly: a clue for a personalized therapy?
    Leuk Lymphoma. 2020 Jan 13:1-4. doi: 10.1080/10428194.2019.1709833.
    PubMed    


  275. PARIKH SA, Meacham PJ, Zent CS, Evans AG, et al
    Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications.
    Leuk Lymphoma. 2020 Jan 11:1-15. doi: 10.1080/10428194.2019.1709830.
    PubMed     Abstract available


  276. CHEN G, Zhou W, Gong D, Li Y, et al
    Loss of X chromosome predicts favorable prognosis in female patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jan 9:1-10. doi: 10.1080/10428194.2019.1709836.
    PubMed     Abstract available


  277. BUCKLEY SA, Halpern AB, Othus M, Jimenez-Sahagun D, et al
    Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2020 Jan 7:1-10. doi: 10.1080/10428194.2019.1709838.
    PubMed     Abstract available


  278. IVANOV V, Farnault L, Mercier C, Colavolpe C, et al
    Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2020 Jan 3:1-4. doi: 10.1080/10428194.2019.1706737.
    PubMed    


  279. BROWN AL, Hahn C, Hiwase D, Godley LA, et al
    Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis.
    Leuk Lymphoma. 2020;61:246-247.
    PubMed    


  280. PRIETO-CONDE MI, Labrador J, Hermida G, Alonso S, et al
    Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis'.
    Leuk Lymphoma. 2020;61:248-249.
    PubMed    


    December 2019
  281. TAKAHASHI T, Ichikawa S, Ichinohasama R, Harigae H, et al
    BCR-ABL1 positive lymphoblastic lymphoma - should it be treated like a B-lymphoblastic leukemia with t(9;22);BCR-ABL1?
    Leuk Lymphoma. 2019 Dec 26:1-3. doi: 10.1080/10428194.2019.1706736.
    PubMed    


  282. NI J, Hong J, Zhang Z, Li Q, et al
    Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Dec 20:1-6. doi: 10.1080/10428194.2019.1702186.
    PubMed     Abstract available


  283. INBAR T, Sobeh Khalil S, Ram R, Ganzel C, et al
    Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infection.
    Leuk Lymphoma. 2019 Dec 20:1-3. doi: 10.1080/10428194.2019.1702187.
    PubMed    


  284. STUCKERT AJ, Schafer ES, Bernhardt MB, Baxter P, et al
    Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL).
    Leuk Lymphoma. 2019 Dec 16:1-4. doi: 10.1080/10428194.2019.1702183.
    PubMed    


  285. PEJSA V, Lucijanic M, Vrkljan Vuk A, Stoos-Veic T, et al
    Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Dec 16:1-6. doi: 10.1080/10428194.2019.1702182.
    PubMed     Abstract available


  286. TRUONG H, Sierzchulski AG, Schram S, Litzow M, et al
    Systemic methotrexate absorption in a patient receiving intrathecal chemotherapy for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Dec 13:1-3. doi: 10.1080/10428194.2019.1702184.
    PubMed    


  287. SCHULTZ MJ, Blackburn PR, Cogbill CH, Pitel BA, et al
    Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies.
    Leuk Lymphoma. 2019 Dec 6:1-4. doi: 10.1080/10428194.2019.1699081.
    PubMed    


  288. SAITO S, Taira C, Matsuda K, Yanagisawa R, et al
    Complete measurable residual disease response after combination chemotherapy with AML-type and ALL-type regimens in pediatric B/myeloid acute bilineal leukemia.
    Leuk Lymphoma. 2019 Dec 6:1-4. doi: 10.1080/10428194.2019.1697813.
    PubMed    


  289. YANG W, Tholpady A, Casteel KN, Rojas-Hernandez C, et al
    Platelet-refractoriness and the clinical impact in leukemia population at a metropolitan academic cancer center.
    Leuk Lymphoma. 2019 Dec 4:1-3. doi: 10.1080/10428194.2019.1697810.
    PubMed    


  290. STAHL M, Tallman MS
    Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all.
    Leuk Lymphoma. 2019;60:3107-3115.
    PubMed     Abstract available


    November 2019
  291. KOLITZ JE, Strickland SA, Cortes JE, Hogge D, et al
    Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
    Leuk Lymphoma. 2019 Nov 25:1-10. doi: 10.1080/10428194.2019.1688320.
    PubMed     Abstract available


  292. GUAN W, Jing Y, Dou L, Wang M, et al
    Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
    Leuk Lymphoma. 2019 Nov 22:1-7. doi: 10.1080/10428194.2019.1691195.
    PubMed     Abstract available


  293. FOX TA, Halsey R, Pomplun S, Gant V, et al
    Rapid clinical response to adjuvant corticosteroids in chronic disseminated candidiasis complicated by granulomas and persistent fever in acute leukemia patients.
    Leuk Lymphoma. 2019 Nov 22:1-6. doi: 10.1080/10428194.2019.1691198.
    PubMed    


  294. MOLICA M, Breccia M, Capria S, Trisolini S, et al
    The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
    Leuk Lymphoma. 2019 Nov 22:1-10. doi: 10.1080/10428194.2019.1672060.
    PubMed     Abstract available


  295. CHUA CC, Grigg A, Singh J, Droogleever MP, et al
    Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals.
    Leuk Lymphoma. 2019 Nov 21:1-7. doi: 10.1080/10428194.2019.1691192.
    PubMed     Abstract available


  296. HERNANDEZ-MARQUES C, Andion M, Perez-Somarriba M, Madero L, et al
    Can monitoring asparaginase activity help us to manage toxicity in pediatric acute lymphoblastic leukemia?
    Leuk Lymphoma. 2019 Nov 21:1-3. doi: 10.1080/10428194.2019.1691191.
    PubMed    


  297. BHAT SA, Woyach JA
    Changing landscape of frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Nov 15:1-11. doi: 10.1080/10428194.2019.1688321.
    PubMed     Abstract available


  298. MOLICA S, Giannarelli D, Shanafelt TD
    Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis.
    Leuk Lymphoma. 2019 Nov 14:1-4. doi: 10.1080/10428194.2019.1691193.
    PubMed    


  299. ZHOU W, Chen G, Gong D, Li Y, et al
    Loss of the Y chromosome predicts a high relapse risk in younger adult male patients with t(8;21) acute myeloid leukemia on high-dose cytarabine consolidation therapy: a retrospective multicenter study.
    Leuk Lymphoma. 2019 Nov 14:1-11. doi: 10.1080/10428194.2019.1683734.
    PubMed     Abstract available


  300. MAFFEI R, Benatti S, Atene CG, Debbia G, et al
    Selective inhibition of PI3Kgamma affects survival and proliferation of chronic lymphocytic leukemia B cells.
    Leuk Lymphoma. 2019 Nov 14:1-5. doi: 10.1080/10428194.2019.1666376.
    PubMed    


  301. WANG N, Desai A, Ge B, Li W, et al
    Prognostic value of hypoalbuminemia at diagnosis in de novo non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2019 Nov 13:1-9. doi: 10.1080/10428194.2019.1686499.
    PubMed     Abstract available


  302. CHRISTOFORIDOU A, Bezirgiannidou Z, Vrachiolias G, Papoutselis M, et al
    B-cell prolymphocytic leukemia successfully treated with B-cell receptor antagonists, but resistant to venetoclax.
    Leuk Lymphoma. 2019 Nov 12:1-4. doi: 10.1080/10428194.2019.1689392.
    PubMed    


  303. CERRANO M, Seegers V, Raffoux E, Rabian F, et al
    Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis.
    Leuk Lymphoma. 2019 Nov 11:1-4. doi: 10.1080/10428194.2019.1683735.
    PubMed    


  304. SHIMOMURA Y, Hara M, Maruoka H, Yabushita T, et al
    Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 Nov 11:1-4. doi: 10.1080/10428194.2019.1686500.
    PubMed    


  305. TCHENG M, Samudio I, Spagnuolo PA
    Inhibitors of fatty acid oxidation enhance death of acute myeloid leukemia cells lacking NIX or SQSTM1.
    Leuk Lymphoma. 2019 Nov 11:1-4. doi: 10.1080/10428194.2019.1682570.
    PubMed    


  306. WEIDE R, Feiten S, Chakupurakal G, Friesenhahn V, et al
    Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017.
    Leuk Lymphoma. 2019 Nov 4:1-10. doi: 10.1080/10428194.2019.1680840.
    PubMed     Abstract available


  307. DERMAN BA, Streck M, Wynne J, Christ TN, et al
    Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Nov 4:1-9. doi: 10.1080/10428194.2019.1680839.
    PubMed     Abstract available


    October 2019
  308. PLUTA A, Robak T, Brzozowski K, Stepka K, et al
    Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
    Leuk Lymphoma. 2019 Oct 29:1-16. doi: 10.1080/10428194.2019.1678151.
    PubMed     Abstract available


  309. SHAH NP, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, et al
    Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study.
    Leuk Lymphoma. 2019 Oct 24:1-10. doi: 10.1080/10428194.2019.1675879.
    PubMed     Abstract available


  310. IVANOV OFVERHOLM I, Zachariadis V, Taylan F, Marincevic-Zuniga Y, et al
    Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Oct 22:1-10. doi: 10.1080/10428194.2019.1678153.
    PubMed     Abstract available


  311. ZHANG P, Ruan J, Weng W, Tang Y, et al
    Overexpression of SET and MYND domain-containing protein 2 (SMYD2) is associated with poor prognosis in pediatric B lineage acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Oct 15:1-8. doi: 10.1080/10428194.2019.1675875.
    PubMed     Abstract available


  312. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.
    PubMed    


  313. MELEVEEDU KS, Chen D, Nadiminti K, Sidiqi H, et al
    PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia.
    Leuk Lymphoma. 2019 Oct 12:1-4. doi: 10.1080/10428194.2019.1675880.
    PubMed    


  314. KOHART NA, Elshafae SM, Demirer AA, Dirksen WP, et al
    Parathyroid hormone-related protein promotes bone loss in T-cell leukemia as well as in solid tumors.
    Leuk Lymphoma. 2019 Oct 8:1-11. doi: 10.1080/10428194.2019.1672055.
    PubMed     Abstract available


  315. LECAT CSY, Besley C, Hough RE, Khwaja A, et al
    Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data.
    Leuk Lymphoma. 2019 Oct 3:1-3. doi: 10.1080/10428194.2019.1672057.
    PubMed    


    September 2019
  316. ALFAYEZ M, Thakral B, Jain P, Ravandi F, et al
    First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL).
    Leuk Lymphoma. 2019 Sep 30:1-5. doi: 10.1080/10428194.2019.1660967.
    PubMed    


  317. MYLES N, Giri P, Chim I, Kodituwakku A, et al
    The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry.
    Leuk Lymphoma. 2019 Sep 27:1-3. doi: 10.1080/10428194.2019.1663420.
    PubMed    


  318. FAZIO F, Barberi W, Cazzaniga G, Fazio G, et al
    Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript.
    Leuk Lymphoma. 2019 Sep 27:1-4. doi: 10.1080/10428194.2019.1668938.
    PubMed    


  319. GURBUXANI S
    Lymphoblastic leukemia following MDS or MDS/MPN: clinical evidence for stem cell origins of these disorders.
    Leuk Lymphoma. 2019 Sep 26:1-2. doi: 10.1080/10428194.2019.1666382.
    PubMed    


  320. ANDREWS C, Lipton J
    The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
    Leuk Lymphoma. 2019 Sep 26:1-3. doi: 10.1080/10428194.2019.1665667.
    PubMed    


  321. DENG R, Gibiansky L, Lu T, Li X, et al
    Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
    Leuk Lymphoma. 2019 Sep 24:1-10. doi: 10.1080/10428194.2019.1657575.
    PubMed     Abstract available


  322. MULLIGAN SP, Shumack S, Guminski A
    Chronic lymphocytic leukemia, skin and other second cancers.
    Leuk Lymphoma. 2019 Sep 24:1-3. doi: 10.1080/10428194.2019.1665669.
    PubMed    


  323. ZHANG H, Ying H, Wang X
    Methyltransferase DNMT3B in leukemia.
    Leuk Lymphoma. 2019 Sep 24:1-11. doi: 10.1080/10428194.2019.1666377.
    PubMed     Abstract available


  324. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
    Leuk Lymphoma. 2019 Sep 23:1-10. doi: 10.1080/10428194.2019.1665664.
    PubMed     Abstract available


  325. XU H, Liu J, Shen N, Zhao Z, et al
    The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia.
    Leuk Lymphoma. 2019 Sep 18:1-10. doi: 10.1080/10428194.2019.1658098.
    PubMed     Abstract available


  326. SEA JL, Orgel E, Chen T, Paszkiewicz RL, et al
    Levocarnitine does not impair chemotherapy cytotoxicity against acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 16:1-9. doi: 10.1080/10428194.2019.1666379.
    PubMed     Abstract available


  327. WANG F, Liu T, Wang L, Gu Z, et al
    Unmanipulated haploidentical peripheral blood stem cell transplantation for patients with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission.
    Leuk Lymphoma. 2019 Sep 13:1-10. doi: 10.1080/10428194.2019.1660965.
    PubMed     Abstract available


  328. OKABE S, Tanaka Y, Moriyama M, Gotoh A, et al
    Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
    Leuk Lymphoma. 2019 Sep 10:1-3. doi: 10.1080/10428194.2019.1660971.
    PubMed    


  329. YANG Q, Qian H, Jin Z, Yu Z, et al
    SET-CAN fusion gene as poor prognosis predictor in adult T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 10:1-4. doi: 10.1080/10428194.2019.1660966.
    PubMed    


  330. NAGAI Y, Tsukamoto S, Hino Y, Isshiki Y, et al
    Remarkable donor-derived T cell lymphocytosis before engraftment of a bone marrow transplant for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 5:1-4. doi: 10.1080/10428194.2019.1660973.
    PubMed    


  331. LANVERS-KAMINSKY C, Niemann A, Eveslage M, Beck J, et al
    Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Sep 3:1-8. doi: 10.1080/10428194.2019.1658099.
    PubMed     Abstract available


    August 2019
  332. BALDUCCI E, Sanekli S, Hugues P, Soubeyrand M, et al
    Co-occurrence of BCR-ABL1 rearrangement and CALR mutation in a single leukemic stem cell: evidence that BCR-ABL1 oncogenic addiction prevails over CALR signaling.
    Leuk Lymphoma. 2019 Aug 29:1-4. doi: 10.1080/10428194.2019.1658101.
    PubMed    


  333. ADVANI AS, Hanna R
    The treatment of adolescents and young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Aug 27:1-9. doi: 10.1080/10428194.2019.1658103.
    PubMed     Abstract available


  334. CORTES J, Huynh L, Mendelson E, Brandt P, et al
    Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.
    Leuk Lymphoma. 2019 Aug 13:1-10. doi: 10.1080/10428194.2019.1644332.
    PubMed     Abstract available


  335. WONG E, Davis J, Koldej R, Szer J, et al
    Nivolumab induces dynamic alterations in CD8 T-cell function and TIM-3 expression when used to treat relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Aug 7:1-4. doi: 10.1080/10428194.2019.1648803.
    PubMed    


  336. RATAJCZAK B, Gniot M, Przybylowicz-Chalecka A, Czerwinska-Rybak J, et al
    Characterization and significance of the Philadelphia negative/BCR-ABL1 positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.
    Leuk Lymphoma. 2019 Aug 7:1-5. doi: 10.1080/10428194.2019.1648807.
    PubMed    


  337. PRIETO-CONDE MI, Labrador J, Hermida G, Alonso S, et al
    Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder.
    Leuk Lymphoma. 2019 Aug 6:1-4. doi: 10.1080/10428194.2019.1648801.
    PubMed    


    July 2019
  338. GU JX, Zhang N, Li SS, Zhang AM, et al
    The detection of bacterial infections in leukemia patients using procalcitionin levels.
    Leuk Lymphoma. 2019 Jul 27:1-6. doi: 10.1080/10428194.2019.1646906.
    PubMed     Abstract available


  339. ANDRITSOS LA, Byrd JC, Cheverton P, Wu J, et al
    A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 27:1-9. doi: 10.1080/10428194.2019.1643463.
    PubMed     Abstract available


  340. PAIGE E, Thursky K, Slavin M
    Mold-active prophylaxis in acute leukemia: not enough of a good thing?()
    Leuk Lymphoma. 2019 Jul 23:1-3. doi: 10.1080/10428194.2019.1641804.
    PubMed    


  341. KNORR DA, Goldberg AD, Stein EM, Tallman MS, et al
    Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.
    Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167.
    PubMed     Abstract available


  342. DHAKAL P, Kaur J, Gundabolu K, Raj Bhatt V, et al
    Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?
    Leuk Lymphoma. 2019 Jul 18:1-11. doi: 10.1080/10428194.2019.1641802.
    PubMed     Abstract available


  343. CHEN Z, Mai W, Li Z, Zhang H, et al
    The epidemiological trend of acute promyelocytic leukemia over past four decades: a population-based analysis.
    Leuk Lymphoma. 2019 Jul 15:1-12. doi: 10.1080/10428194.2019.1639164.
    PubMed     Abstract available


  344. ALFAYEZ M, Burger JA, Kadia T, Xu TH, et al
    Plesiomonas shigelloides gastroenteritis in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jul 15:1-2. doi: 10.1080/10428194.2019.1639171.
    PubMed    


  345. BARRETO JN, Cullen MW, Mara KC, Grove ME, et al
    QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia.
    Leuk Lymphoma. 2019 Jul 12:1-9. doi: 10.1080/10428194.2019.1639165.
    PubMed     Abstract available


  346. BASSAN R, Fumagalli M, Chiaretti S, Audisio E, et al
    Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol.
    Leuk Lymphoma. 2019 Jul 12:1-11. doi: 10.1080/10428194.2019.1639170.
    PubMed     Abstract available


  347. AUTORE F, Sora F, Chiusolo P, Annunziata M, et al
    'Secondary chronic myeloid leukemia': comparison between patients previously exposed or not to chemo- and/or radiotherapy.
    Leuk Lymphoma. 2019 Jul 11:1-3. doi: 10.1080/10428194.2019.1639162.
    PubMed    


  348. HICKEY E, Clemons B, Griffin S, Cox J, et al
    Multicenter evaluation of arsenic trioxide dosing in obese patients with low-intermediate risk acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Jul 11:1-4. doi: 10.1080/10428194.2019.1639163.
    PubMed    


  349. HARADA K, Tachibana T, Ohashi K, Ozawa Y, et al
    The effect of melphalan dose and total body irradiation as reduced-intensity conditioning for acute lymphoblastic leukemia patients undergoing allogeneic stem cell transplantation.
    Leuk Lymphoma. 2019 Jul 10:1-8. doi: 10.1080/10428194.2019.1636986.
    PubMed     Abstract available


  350. SHENG G, Xue M, Wang Q, Wen L, et al
    Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments.
    Leuk Lymphoma. 2019 Jul 8:1-9. doi: 10.1080/10428194.2019.1636984.
    PubMed     Abstract available


  351. MUESKE NM, Mittelman SD, Wren TAL, Gilsanz V, et al
    Myosteatosis in adolescents and young adults treated for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jul 2:1-8. doi: 10.1080/10428194.2019.1623889.
    PubMed     Abstract available


  352. CHOE HK, van Besien K
    Donor graft genotypes versus leukemia.
    Leuk Lymphoma. 2019;60:1606-1607.
    PubMed    


  353. XUE M, Wang Q, Huo L, Wen L, et al
    Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
    Leuk Lymphoma. 2019 Jul 1:1-7. doi: 10.1080/10428194.2019.1607329.
    PubMed     Abstract available


  354. MEHER-HOMJI Z, Tam CS, Siderov J, Seymour JF, et al
    High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
    Leuk Lymphoma. 2019 Jul 1:1-6. doi: 10.1080/10428194.2019.1633640.
    PubMed     Abstract available


  355. WANG F, Chen Y, Jiang N, Gong S, et al
    Acquired persistently complete remission by decitabine-based treatment for acute myeloid leukemia with the MLL-SEPT9 fusion gene.
    Leuk Lymphoma. 2019 Jul 1:1-4. doi: 10.1080/10428194.2019.1625044.
    PubMed    


    June 2019
  356. ISHDORJ G, Beiggi S, Nugent Z, Streu E, et al
    Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival.
    Leuk Lymphoma. 2019 Jun 25:1-10. doi: 10.1080/10428194.2019.1620941.
    PubMed     Abstract available


  357. TATE C, Burgess M, McMillan NA, Saunders NA, et al
    High serum levels of CD178 (soluble FasL) predict for inferior progression free survival in chronic lymphocytic leukemia treated with fludarabine-based chemotherapy.
    Leuk Lymphoma. 2019 Jun 25:1-5. doi: 10.1080/10428194.2019.1581936.
    PubMed    


  358. ROSSOFF J, Platanias LC
    Impact of myosteatosis in survivors of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 21:1-2. doi: 10.1080/10428194.2019.1630623.
    PubMed    


  359. SHAHRABI S, Maleknia M, Tavakolifar Y, D Zayeri Z, et al
    Neutropenia and leukemia development: genetic risk factors and prognosis.
    Leuk Lymphoma. 2019 Jun 19:1-12. doi: 10.1080/10428194.2019.1630622.
    PubMed     Abstract available


  360. STAHL M, Tallman MS
    Antibody-based therapy in acute leukemia - beware the risks.
    Leuk Lymphoma. 2019 Jun 17:1-2. doi: 10.1080/10428194.2019.1608535.
    PubMed    


  361. ACUNA-VILLAORDUNA A, Gonzalez-Lugo J, Ye BH, Adrianzen Herrera DA, et al
    High prevalence of pulmonary findings in computed tomographies of HTLV-1-infected patients with and without adult-T cell leukemia/lymphoma - implications for staging.
    Leuk Lymphoma. 2019 Jun 17:1-5. doi: 10.1080/10428194.2019.1627543.
    PubMed     Abstract available


  362. ASTORGUES-XERRI L, Vazquez R, Odore E, Rezai K, et al
    Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
    Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860.
    PubMed    


  363. KIM B, Lee H, Kim E, Shin S, et al
    Clinical utility of targeted NGS panel with comprehensive bioinformatics analysis for patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jun 17:1-8. doi: 10.1080/10428194.2019.1627538.
    PubMed     Abstract available


  364. XU D, Claudiani S, Naresh K, Mucklow S, et al
    Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
    Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101.
    PubMed    


  365. VASSEUR L, Lara D, Clappier E, Gillebert Q, et al
    Common clonal origin of an EBV-positive diffuse large B cell lymphoma and a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Jun 11:1-3. doi: 10.1080/10428194.2019.1627539.
    PubMed    


  366. ELMAAGACLI AH, Salwender H, Jehn C, Dahmash F, et al
    Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1623887.
    PubMed    


  367. IBRAHIM M, Mendis N, Roma A, Jayanth P, et al
    Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1620940.
    PubMed    


  368. CHEN LS, Keating MJ, Wierda WG, Gandhi V, et al
    Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2019 Jun 4:1-4. doi: 10.1080/10428194.2019.1622098.
    PubMed    


  369. DRAGANI M, Rege-Cambrin G, Ferrero D, Abruzzese E, et al
    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-3. doi: 10.1080/10428194.2019.1622103.
    PubMed    


  370. CERRANO M, Candoni A, Crisa E, Dubbini MV, et al
    FLAI induction regimen in elderly patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jun 4:1-2. doi: 10.1080/10428194.2019.1620943.
    PubMed    


  371. KIMURA K, Tsukamoto S, Takaishi K, Isshiki Y, et al
    T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia.
    Leuk Lymphoma. 2019;60:1591-1594.
    PubMed    


    May 2019
  372. ZAJAC-SPYCHALA O, Skalska-Sadowska J, Wachowiak J, Szmydki-Baran A, et al
    Infections in children with acute myeloid leukemia: increased mortality in relapsed/refractory patients.
    Leuk Lymphoma. 2019 May 28:1-8. doi: 10.1080/10428194.2019.1616185.
    PubMed     Abstract available


  373. BODDU P, Jain P, Borthakur G, Verstovsek S, et al
    Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy.
    Leuk Lymphoma. 2019 May 24:1-9. doi: 10.1080/10428194.2019.1617862.
    PubMed     Abstract available


  374. KLOOS RQH, Pieters R, van den Bos C, van Eijkelenburg NKA, et al
    The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 23:1-9. doi: 10.1080/10428194.2019.1613537.
    PubMed     Abstract available


  375. CATTANEO C, Gramegna D, Malagola M, Pagani C, et al
    Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
    Leuk Lymphoma. 2019 May 23:1-7. doi: 10.1080/10428194.2019.1613535.
    PubMed     Abstract available


  376. JOSEPH R, McRee AJ, Mathews S, Zeidner JF, et al
    Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET).
    Leuk Lymphoma. 2019 May 23:1-5. doi: 10.1080/10428194.2019.1612060.
    PubMed    


  377. BEST S, Liu T, Bruss N, Kittai A, et al
    Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells.
    Leuk Lymphoma. 2019 May 21:1-5. doi: 10.1080/10428194.2019.1616190.
    PubMed     Abstract available


  378. TORMO M, Gimenez E, Calabuig M, Talaya A, et al
    Cytomegalovirus DNAemia in patients with de novo acute myeloid leukemia undergoing cytotoxic chemotherapy.
    Leuk Lymphoma. 2019 May 21:1-3. doi: 10.1080/10428194.2019.1613541.
    PubMed    


  379. PUN CC, Lee KK, Chui YL
    C-terminal BRE inhibits cellular proliferation and increases sensitivity to chemotherapeutic drugs of MLL-AF9 acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 May 21:1-9. doi: 10.1080/10428194.2019.1616184.
    PubMed     Abstract available


  380. DURAND M, Lacaria K, Sidsworth M, Davis MK, et al
    Management of cardiovascular health in acute leukemia: a national survey.
    Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1613539.
    PubMed     Abstract available


  381. INNOCENTI I, Morelli F, Autore F, Tomasso A, et al
    Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax.
    Leuk Lymphoma. 2019 May 20:1-3. doi: 10.1080/10428194.2019.1612063.
    PubMed    


  382. SHIMAZU Y, Nohgawa M
    Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma.
    Leuk Lymphoma. 2019 May 20:1-2. doi: 10.1080/10428194.2019.1616188.
    PubMed    


  383. PAIGE E, Haywood P, Xie M, Worth L, et al
    Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program.
    Leuk Lymphoma. 2019 May 17:1-11. doi: 10.1080/10428194.2019.1590570.
    PubMed     Abstract available


  384. RAFEI H, Kantarjian HM, Jabbour EJ
    Recent advances in the treatment of acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 16:1-16. doi: 10.1080/10428194.2019.1605071.
    PubMed     Abstract available


  385. SOUMERAI JD, Davids MS, Werner L, Fisher DC, et al
    Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533.
    PubMed     Abstract available


  386. SALAMERO O, Martinez-Cuadron D, Sobas M, Benavente C, et al
    Real life outcomes of patients aged >/=75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry.
    Leuk Lymphoma. 2019 May 9:1-13. doi: 10.1080/10428194.2019.1607327.
    PubMed     Abstract available


  387. KREITMAN RJ
    Hairy cell leukemia: present and future directions.
    Leuk Lymphoma. 2019 May 9:1-11. doi: 10.1080/10428194.2019.1608536.
    PubMed     Abstract available


  388. TAKEDA R, Yokoyama K, Ogawa M, Kawamata T, et al
    The first case of elderly TCF3-HLF-positive B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 6:1-4. doi: 10.1080/10428194.2019.1602267.
    PubMed    


  389. ZHANG X, Guo X
    Coexistence of BCR/ABL1 p190 transcript and CEBPA double mutations in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1608532.
    PubMed    


  390. DELLA STARZA I, De Novi LA, Santoro A, Salemi D, et al
    Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 May 3:1-3. doi: 10.1080/10428194.2019.1607325.
    PubMed    


  391. REFAEI M, Radhwi O, Sandhu I, Brandwein J, et al
    A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2019 May 2:1-9. doi: 10.1080/10428194.2018.1543878.
    PubMed     Abstract available


    April 2019
  392. ZHANG X, Huang X, Xu H, Li J, et al
    MLL-rearrangement can resemble acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Apr 30:1-3. doi: 10.1080/10428194.2019.1607328.
    PubMed    


  393. GABELLI M, Disaro S, Scarparo P, Francescato S, et al
    Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 25:1-4. doi: 10.1080/10428194.2019.1602269.
    PubMed    


  394. XIE W, Chen Z, Wang SA, Hu S, et al
    Lymphoblastic leukemia following myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
    Leuk Lymphoma. 2019 Apr 24:1-9. doi: 10.1080/10428194.2019.1605509.
    PubMed     Abstract available


  395. BEZERRA ED, Flowers ME, Onstad LE, Chielens D, et al
    A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1605508.
    PubMed     Abstract available


  396. HAMPEL PJ, Ding W, Call TG, Rabe KG, et al
    Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.
    Leuk Lymphoma. 2019 Apr 24:1-8. doi: 10.1080/10428194.2019.1602268.
    PubMed     Abstract available


  397. ALDOSS I, Pullarkat V
    Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1.
    Leuk Lymphoma. 2019 Apr 24:1-3. doi: 10.1080/10428194.2019.1605510.
    PubMed    


  398. TALLIS E, Loghavi S, Jorgensen JL, Wang S, et al
    Patient with mixed-phenotype acute leukemia with CBFB rearrangement.
    Leuk Lymphoma. 2019 Apr 23:1-3. doi: 10.1080/10428194.2019.1605069.
    PubMed    


  399. TOTH LN, Green D, Peterson J, Deharvengt SJ, et al
    Variant allele frequencies do not correlate well with myeloblast counts in a clinically validated gene sequencing panel for routine acute myeloid leukemia workup.
    Leuk Lymphoma. 2019 Apr 18:1-8. doi: 10.1080/10428194.2019.1587757.
    PubMed     Abstract available


  400. GOMEZ-ARTEAGA A, Margolskee E, Wei MT, van Besien K, et al
    Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.
    Leuk Lymphoma. 2019 Apr 18:1-6. doi: 10.1080/10428194.2019.1594220.
    PubMed    


  401. FRAISON JB, Grignano E, Braun T, Ades L, et al
    Autoantibodies in myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2019 Apr 8:1-3. doi: 10.1080/10428194.2019.1599114.
    PubMed    


  402. XU M, Liu H, Liu Y, Ma X, et al
    Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-10. doi: 10.1080/10428194.2019.1597270.
    PubMed     Abstract available


  403. TSIROGIANNI M, Grigoriou E, Kapsimalli V, Dagla K, et al
    Natural killer cell cytotoxicity is a predictor of outcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine.
    Leuk Lymphoma. 2019 Apr 5:1-7. doi: 10.1080/10428194.2019.1581935.
    PubMed     Abstract available


  404. DOMBRET H, Topp MS, Schuh AC, Wei AH, et al
    Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Apr 5:1-9. doi: 10.1080/10428194.2019.1576872.
    PubMed     Abstract available


  405. BEYAR-KATZ O, Lavi N, Ringelstein-Harlev S, Henig I, et al
    Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
    Leuk Lymphoma. 2019 Apr 3:1-8. doi: 10.1080/10428194.2019.1594214.
    PubMed     Abstract available


    March 2019
  406. DESHIELDS TL, Dueck AC, Rogers K, Brown JR, et al
    Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).
    Leuk Lymphoma. 2019 Mar 27:1-4. doi: 10.1080/10428194.2019.1594218.
    PubMed    


  407. BERDEJA JG, Heinrich MC, Dakhil SR, Goldberg SL, et al
    Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
    Leuk Lymphoma. 2019 Mar 26:1-10. doi: 10.1080/10428194.2019.1590569.
    PubMed     Abstract available


  408. BUCKLEY SA, Mark NM, Othus M, Estey EH, et al
    Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.
    Leuk Lymphoma. 2019 Mar 11:1-4. doi: 10.1080/10428194.2019.1581933.
    PubMed    


  409. NAYMAGON L, Moshier E, Tremblay D, Mascarenhas J, et al
    Predictors of early hemorrhage in acute promyelocytic leukemia.
    Leuk Lymphoma. 2019 Mar 8:1-10. doi: 10.1080/10428194.2019.1581187.
    PubMed     Abstract available


    February 2019
  410. SALEHI S, Astle JM, Sadigh S, Lake J, et al
    Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA.
    Leuk Lymphoma. 2019 Feb 26:1-5. doi: 10.1080/10428194.2019.1581927.
    PubMed    


  411. KONUMA T, Kato S, Oiwa-Monna M, Mizusawa M, et al
    Myeloablative single-unit cord blood transplantation overcomes the negative prognostic impact of FLT3-ITD in adult acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1579325.
    PubMed    


  412. PELLAND-MARCOTTE MC, Hwee J, Pole JD, Nathan PC, et al
    Incidence of infections after therapy completion in children with acute lymphoblastic leukemia or acute myeloid leukemia: a systematic review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-11. doi: 10.1080/10428194.2019.1573369.
    PubMed     Abstract available


  413. JAROSOVA M, Plevova K, Kotaskova J, Doubek M, et al
    The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
    Leuk Lymphoma. 2019 Feb 18:1-8. doi: 10.1080/10428194.2019.1576038.
    PubMed     Abstract available


  414. LAI TH, Mitchell S, Wu PJ, Orwick S, et al
    HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1571197.
    PubMed    


  415. PEROL L, Grignano E, Contejean A, Gastaud L, et al
    High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
    Leuk Lymphoma. 2019 Feb 18:1-4. doi: 10.1080/10428194.2019.1577414.
    PubMed    


  416. DENG DX, Zhu HH, Liu YR, Chang YJ, et al
    Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.
    Leuk Lymphoma. 2019 Feb 18:1-9. doi: 10.1080/10428194.2019.1576868.
    PubMed     Abstract available


  417. DAI K, Zhang Q, Li Y, Wu L, et al
    Plasma fibrinogen levels correlate with prognosis and treatment outcome in patients with non-M3 acute myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 8:1-9. doi: 10.1080/10428194.2018.1535116.
    PubMed     Abstract available


  418. WINESTONE LE, Getz KD, Rao P, Li Y, et al
    Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.
    Leuk Lymphoma. 2019 Feb 7:1-9. doi: 10.1080/10428194.2019.1574002.
    PubMed     Abstract available


  419. BOSE P, Chen LS, Gandhi V
    Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'.
    Leuk Lymphoma. 2019 Feb 6:1-3. doi: 10.1080/10428194.2019.1571207.
    PubMed    


  420. XU Y, Zhou X, Li Y, Zhang Y, et al
    Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine.
    Leuk Lymphoma. 2019 Feb 4:1-9. doi: 10.1080/10428194.2018.1523400.
    PubMed     Abstract available


  421. ZHANG J, Yang F, Qiu HY, Wu Q, et al
    Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Leuk Lymphoma. 2019 Feb 4:1-8. doi: 10.1080/10428194.2018.1533127.
    PubMed     Abstract available


  422. NATARAJAN H
    Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571206.
    PubMed    


  423. ESKAZAN AE
    Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?
    Leuk Lymphoma. 2019 Feb 4:1-2. doi: 10.1080/10428194.2019.1571202.
    PubMed    


  424. MCCARTER SJ, Vijayvargiya P, Sidana S, Nault AM, et al
    A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses.
    Leuk Lymphoma. 2019;60:559-561.
    PubMed    


    January 2019
  425. ARGYROU C, Hatziagapiou K, Theodorakidou M, Nikola OA, et al
    The role of adiponectin, LEPTIN, and ghrelin in the progress and prognosis of childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 30:1-12. doi: 10.1080/10428194.2019.1569230.
    PubMed     Abstract available


  426. RITCHIE EK, Latremouille-Viau D, Guerin A, Pivneva I, et al
    Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.
    Leuk Lymphoma. 2019 Jan 22:1-9. doi: 10.1080/10428194.2018.1538510.
    PubMed     Abstract available


  427. KHOT A
    Where do we currently stand with T-cell prolymphocytic leukemia?
    Leuk Lymphoma. 2019 Jan 22:1-3. doi: 10.1080/10428194.2018.1551543.
    PubMed    


  428. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Sorokina TV, et al
    Alterations in multipotent mesenchymal stromal cells from the bone marrow of acute myeloid leukemia patients at diagnosis and during treatment.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1554861.
    PubMed     Abstract available


  429. ECTOR GICG, Govers TM, Westerweel PE, Grutters JPC, et al
    The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 22:1-8. doi: 10.1080/10428194.2018.1535113.
    PubMed     Abstract available


  430. BEWERSDORF JP, Stahl M, Zeidan AM
    Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
    Leuk Lymphoma. 2019 Jan 17:1-16. doi: 10.1080/10428194.2018.1546854.
    PubMed     Abstract available


  431. KERMEZLI Y, Saadi W, Belhocine M, Mathieu EL, et al
    A comprehensive catalog of LncRNAs expressed in T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2019 Jan 16:1-13. doi: 10.1080/10428194.2018.1551534.
    PubMed     Abstract available


  432. SHEN Y, Crassini K, Sandhu S, Fatima N, et al
    Dual inhibition of MEK1/2 and AKT by binimetinib and MK2206 induces apoptosis of chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment.
    Leuk Lymphoma. 2019 Jan 16:1-12. doi: 10.1080/10428194.2018.1542148.
    PubMed     Abstract available


  433. QUINTAS-CARDAMA A
    CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.
    Leuk Lymphoma. 2019 Jan 16:1-3. doi: 10.1080/10428194.2018.1533132.
    PubMed    


  434. AWAN FT, Thirman MJ, Patel-Donnelly D, Assouline S, et al
    Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
    Leuk Lymphoma. 2019 Jan 11:1-6. doi: 10.1080/10428194.2018.1562180.
    PubMed     Abstract available


  435. ZHANG X, Li F, Wang J, Suo S, et al
    RARgamma-rearrangements resemble acute promyelocytic leukemia and benefit from 3 + 7 regimen.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1553302.
    PubMed    


  436. ALBERTSEN BK, Harila-Saari A, Jahnukainen K, Lahteenmaki P, et al
    Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1538507.
    PubMed     Abstract available


  437. LASICA M, Willcox A, Burbury K, Ross DM, et al
    The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-7. doi: 10.1080/10428194.2018.1551533.
    PubMed     Abstract available


  438. BODDU P, Gibbons J, Burger J, Sivina M, et al
    Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1547902.
    PubMed    


  439. TEH BW, Chui W, Handunnetti S, Tam C, et al
    High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-4. doi: 10.1080/10428194.2018.1543884.
    PubMed    


  440. SADIGH S, Morrissette JJD, Bagg A
    FBXW7 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 11:1-2. doi: 10.1080/10428194.2018.1537488.
    PubMed    


  441. DANESE MD, Katz A, Cetin K, Chia V, et al
    Treatment patterns, survival, and hospitalization in adult patients with acute lymphoblastic leukemia: an observational cohort study using SEER Medicare data.
    Leuk Lymphoma. 2019 Jan 11:1-10. doi: 10.1080/10428194.2018.1555329.
    PubMed     Abstract available


  442. ESTEY E
    'Looking beyond survival to define therapeutic value in acute myeloid leukemia'.
    Leuk Lymphoma. 2019 Jan 10:1-3. doi: 10.1080/10428194.2018.1543886.
    PubMed    


  443. MA H, Padmanabhan Iyer S, Parmar S, Gong Y, et al
    Adoptive cell therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1553300.
    PubMed     Abstract available


  444. SCHORE RJ, Devidas M, Bleyer A, Reaman GH, et al
    Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4().
    Leuk Lymphoma. 2019 Jan 10:1-9. doi: 10.1080/10428194.2018.1542146.
    PubMed     Abstract available


  445. WANG Q, Wan J, Zhang W, Hao S, et al
    MCL-1 or BCL-xL-dependent resistance to the BCL-2 antagonist (ABT-199) can be overcome by specific inhibitor as single agents and in combination with ABT-199 in acute myeloid leukemia cells.
    Leuk Lymphoma. 2019 Jan 10:1-11. doi: 10.1080/10428194.2018.1563694.
    PubMed     Abstract available


  446. CHAOUI D, Hacini M, Fitoussi O, Karlin L, et al
    Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
    Leuk Lymphoma. 2019 Jan 9:1-5. doi: 10.1080/10428194.2018.1533130.
    PubMed    


  447. FOURNIER E, Inchiappa L, Delattre C, Pignon JM, et al
    Increased risk of adverse acute myeloid leukemia after anti-CD19-targeted immunotherapies in KMT2A-rearranged acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2019 Jan 7:1-4. doi: 10.1080/10428194.2018.1562185.
    PubMed    


  448. AKHTAR OS, Attwood K, Lund I, Hare R, et al
    Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2019 Jan 2:1-6. doi: 10.1080/10428194.2018.1554862.
    PubMed     Abstract available


  449. KNORR KLB, Tallman MS
    LeukeMYC prognostication.
    Leuk Lymphoma. 2019;60:1-2.
    PubMed    


  450. SCHRAMM F, Zimmermann M, Jorch N, Pekrun A, et al
    Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09.
    Leuk Lymphoma. 2019;60:60-68.
    PubMed     Abstract available


  451. AMPATZIDOU M, Paterakis G, Vasdekis V, Papadhimitriou SI, et al
    Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL.
    Leuk Lymphoma. 2019;60:258-261.
    PubMed    


  452. IHLOW J, Gross S, Sick A, Schneider T, et al
    AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival.
    Leuk Lymphoma. 2019;60:69-77.
    PubMed     Abstract available


  453. GOVER-PROAKTOR A, Granot G, Pasmanik-Chor M, Pasvolsky O, et al
    Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Leuk Lymphoma. 2019;60:189-199.
    PubMed     Abstract available


  454. ADEHIN A, Adeagbo BA, Kennedy MA, Bolaji OO, et al
    Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
    Leuk Lymphoma. 2019;60:216-221.
    PubMed     Abstract available


  455. GUNTI S, Herman SEM, Gottumukkala RVSRK, Xiong Y, et al
    Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes.
    Leuk Lymphoma. 2019;60:242-245.
    PubMed    


    December 2018
  456. AUTORE F, Chiusolo P, Sora F, Giammarco S, et al
    Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leuk Lymphoma. 2018 Dec 11:1-3. doi: 10.1080/10428194.2018.1522436.
    PubMed    


  457. LABRADOR J, Luno E, Vellenga E, Brunet S, et al
    Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leuk Lymphoma. 2018 Dec 11:1-10. doi: 10.1080/10428194.2018.1522438.
    PubMed     Abstract available


  458. YAMAMOTO K, Yakushijin K, Ichikawa H, Okamura A, et al
    Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
    Leuk Lymphoma. 2018 Dec 11:1-5. doi: 10.1080/10428194.2018.1529311.
    PubMed    


  459. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-6. doi: 10.1080/10428194.2018.1543882.
    PubMed     Abstract available


  460. KIM S, Freeland-Graves JH, Babaei M, Sachdev PK, et al
    Quantifying the association between acute leukemia and serum zinc, copper, and selenium: a meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1540043.
    PubMed     Abstract available


  461. JIANG X, Cheng Y, Hu C, Zhang A, et al
    MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Leuk Lymphoma. 2018 Dec 5:1-12. doi: 10.1080/10428194.2018.1543875.
    PubMed     Abstract available


  462. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Abstract available


  463. MICHAILOV Y, Lunenfeld E, Kapelushnik J, Huleihel M, et al
    Leukemia and male infertility: past, present, and future.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1533126.
    PubMed     Abstract available


    November 2018
  464. NAMN Y, Furman RR, Crawford C
    A rare colonic manifestation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Nov 29:1-4. doi: 10.1080/10428194.2018.1459612.
    PubMed    


  465. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.
    PubMed    


  466. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Abstract available


  467. DIAMANTOPOULOS PT, Kotsianidis I, Symeonidis A, Pappa V, et al
    Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1540783.
    PubMed     Abstract available


  468. SOUMERAI JD, Ni A, Xing G, Huang J, et al
    Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782.
    PubMed     Abstract available


  469. GURU MURTHY GS, Pondaiah SK, Abedin S, Atallah E, et al
    Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
    Leuk Lymphoma. 2018 Nov 8:1-8. doi: 10.1080/10428194.2018.1522442.
    PubMed     Abstract available


  470. NABHAN C, Kamat S, Karl Kish J
    Acute myeloid leukemia in the elderly: what constitutes treatment value?
    Leuk Lymphoma. 2018 Nov 8:1-7. doi: 10.1080/10428194.2018.1520992.
    PubMed     Abstract available


  471. RODRIGUEZ CM, Bussi C, Arroyo DS, Sastre D, et al
    Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Nov 8:1-5. doi: 10.1080/10428194.2018.1529309.
    PubMed    


  472. TAO S, Wang C, Chen Y, Deng Y, et al
    Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1504941.
    PubMed     Abstract available


  473. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Abstract available


    October 2018
  474. POPP HD, Flach J, Brendel S, Ruppenthal S, et al
    Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 31:1-10. doi: 10.1080/10428194.2018.1498494.
    PubMed     Abstract available


  475. ZHANG S, Zhou W, Li Y, Yu S, et al
    Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Leuk Lymphoma. 2018 Oct 17:1-4. doi: 10.1080/10428194.2018.1520991.
    PubMed    


  476. CHEN J, Ngo D, Aldoss I, Shayani S, et al
    Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811.
    PubMed     Abstract available


  477. BHANGOO MS, Saven A
    Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-3. doi: 10.1080/10428194.2018.1519809.
    PubMed    


  478. SOBAS M, Montesinos P, Boluda B, Bernal T, et al
    An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1516875.
    PubMed     Abstract available


  479. DAVIDS MS, Kim HT, Yu L, De Maeyer G, et al
    Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814.
    PubMed     Abstract available


  480. MEI C, Ren Y, Zhou X, Ye L, et al
    Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Leuk Lymphoma. 2018 Oct 10:1-10. doi: 10.1080/10428194.2018.1515938.
    PubMed     Abstract available


  481. LE CLEF Q, Ortega-Sanchez G, Dirnhofer S, Tzankov A, et al
    T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights.
    Leuk Lymphoma. 2018 Oct 10:1-4. doi: 10.1080/10428194.2018.1520993.
    PubMed    


  482. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-3. doi: 10.1080/10428194.2018.1508674.
    PubMed    


  483. NIEBOROWSKA-SKORSKA M, Maifrede S, Ye M, Toma M, et al
    Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-4. doi: 10.1080/10428194.2018.1520988.
    PubMed    


  484. CHEN X, Wang F, Zhang Y, Wang M, et al
    Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1516876.
    PubMed     Abstract available


  485. BUCKLEY SA, Percival ME, Othus M, Halpern AB, et al
    A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036.
    PubMed     Abstract available


  486. MILLER KC, Al-Kali A, Shah MV, Hogan WJ, et al
    Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1509318.
    PubMed     Abstract available


  487. WESTHUS J, Noppeney R, Duhrsen U, Hanoun M, et al
    FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1508670.
    PubMed     Abstract available


  488. BARRIENTOS JC, Burger JA, Byrd JC, Hillmen P, et al
    Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1512710.
    PubMed     Abstract available


  489. SHETH V, Nachmias B, Grisariu S, Avni B, et al
    Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1510495.
    PubMed     Abstract available


  490. CHEN CI, Paul H, Snitzler S, Kakar S, et al
    A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508669.
    PubMed     Abstract available


  491. ROSSOFF J, Akpan I, Platanias LC
    Spontaneous remission in congenital leukemia.
    Leuk Lymphoma. 2018;59:2271-2272.
    PubMed    


    September 2018
  492. D'ARENA G, Seneca E, Migliaccio I, De Feo V, et al
    Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.
    Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.
    PubMed     Abstract available


  493. MCMAHON CM, Perl AE
    Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    Leuk Lymphoma. 2018 Sep 20:1-14. doi: 10.1080/10428194.2018.1504937.
    PubMed     Abstract available


  494. HECKL BC, Carlet M, Vick B, Roolf C, et al
    Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice.
    Leuk Lymphoma. 2018 Sep 20:1-4. doi: 10.1080/10428194.2018.1509314.
    PubMed    


  495. EREN R, Karismaz A, Karatas D, Dogu MH, et al
    Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1509316.
    PubMed     Abstract available


  496. SAENZ-DE-VITERI M, Cudrnak T
    Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2018 Sep 6:1-3. doi: 10.1080/10428194.2018.1508673.
    PubMed    


  497. FERREIRA LAM, Capannacci J, Hokama NK, Nogueira CR, et al
    Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase - chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-7. doi: 10.1080/10428194.2018.1499905.
    PubMed     Abstract available


  498. GIANFELICI V, Messina M, Paoloni F, Peragine N, et al
    IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1499906.
    PubMed    


  499. KNEZ V, Liu X, Schowinsky J, Pan Z, et al
    Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508667.
    PubMed     Abstract available


  500. HE C, Luo B, Jiang N, Liang Y, et al
    OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1480769.
    PubMed     Abstract available


  501. KUTTIKRISHNAN S, Siveen KS, Prabhu KS, Khan AQ, et al
    Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-13. doi: 10.1080/10428194.2018.1494270.
    PubMed     Abstract available


  502. MAZHARUDDIN S, Chattopadhyay A, Levy MY, Redner RL, et al
    IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid.
    Leuk Lymphoma. 2018;59:2246-2249.
    PubMed    


  503. LAMBA JK, Voigt AP, Chauhan L, Shin M, et al
    CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
    Leuk Lymphoma. 2018;59:2250-2253.
    PubMed    


  504. KOMMALAPATI A, Kushchayeva Y, Tella SH
    Incidence, racial disparities and survival outcomes of mast cell malignancies: analysis from a national database.
    Leuk Lymphoma. 2018;59:2254-2257.
    PubMed    


  505. OO ZM, Illendula A, Grembecka J, Schmidt C, et al
    A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFbeta in leukemic cells.
    Leuk Lymphoma. 2018;59:2188-2200.
    PubMed     Abstract available


    August 2018
  506. BORLENGHI E, Cattaneo C, Schieppati F, Gramegna D, et al
    Acute promyelocytic leukemia in patients aged >70 years is not rare and highly curable: a single center series of 21 unselected patients.
    Leuk Lymphoma. 2018 Aug 30:1-4. doi: 10.1080/10428194.2018.1492126.
    PubMed    


  507. CAO M, Carrasco RD, Dubuc AM, Dal Cin P, et al
    ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-3. doi: 10.1080/10428194.2018.1493733.
    PubMed    


  508. SPEZIALI C, Daly A, Abuhaleeqa M, Nitta J, et al
    Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1493734.
    PubMed     Abstract available


  509. JABBOUR EJ, Siegartel LR, Lin J, Lingohr-Smith M, et al
    Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2018 Aug 20:1-7. doi: 10.1080/10428194.2018.1492124.
    PubMed     Abstract available


  510. NATARAJAN H, Kumar L, Bakhshi S, Sharma A, et al
    Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 20:1-8. doi: 10.1080/10428194.2018.1485907.
    PubMed     Abstract available


  511. DELSING MALMBERG E, Johansson Alm S, Nicklasson M, Lazarevic V, et al
    Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910.
    PubMed     Abstract available


  512. OLSHANSKAYA Y, Kazakova A, Tsaur G, Zerkalenkova E, et al
    Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB).
    Leuk Lymphoma. 2018 Aug 1:1-7. doi: 10.1080/10428194.2018.1485904.
    PubMed     Abstract available


  513. WALZ JS, Kowalewski DJ, Backert L, Nelde A, et al
    Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers.
    Leuk Lymphoma. 2018;59:1949-1958.
    PubMed     Abstract available


  514. MA J, Dunlap J, Paliga A, Traer E, et al
    DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
    Leuk Lymphoma. 2018;59:1938-1948.
    PubMed     Abstract available


  515. SHEN Y, Best OG, Mulligan SP, Christopherson RI, et al
    Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.
    Leuk Lymphoma. 2018;59:1927-1937.
    PubMed     Abstract available


  516. AW A, Kim HT, Fernandes SM, Hoang K, et al
    Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.
    Leuk Lymphoma. 2018;59:1986-1989.
    PubMed    


    July 2018
  517. TANEJA A, Jones J, Pittaluga S, Maric I, et al
    Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
    Leuk Lymphoma. 2018 Jul 6:1-4. doi: 10.1080/10428194.2018.1480775.
    PubMed    


  518. XU YP, Wieten L, Wang SX, Cai Y, et al
    Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1474521.
    PubMed     Abstract available


  519. CHELLAPANDIAN D, Pole JD, Nathan PC, Sung L, et al
    Congestive heart failure among children with acute leukemia: a population-based matched cohort study.
    Leuk Lymphoma. 2018 Jul 3:1-10. doi: 10.1080/10428194.2018.1474522.
    PubMed     Abstract available


  520. KAIFIE A, Schikowsky C, Vasko T, Kraus T, et al
    Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1482544.
    PubMed    


  521. KATHIRAVAN M, Singh M, Bhatia P, Trehan A, et al
    Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1482542.
    PubMed     Abstract available


  522. JURCZYSZYN A, Castillo JJ, Avivi I, Czepiel J, et al
    Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
    Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574.
    PubMed     Abstract available


  523. ERBILGIN Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, et al
    Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2018 Jul 2:1-9. doi: 10.1080/10428194.2018.1473573.
    PubMed     Abstract available


  524. STAHL M, DeVeaux M, Montesinos P, Itzykson R, et al
    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893.
    PubMed    


  525. LOZANO C, Brun S, Arnaud A, Gaulard P, et al
    Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1471601.
    PubMed    


  526. SAGLIO G, Jabbour E
    First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
    Leuk Lymphoma. 2018;59:1523-1538.
    PubMed     Abstract available


  527. TANG CPS, McMullen J, Tam C
    Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
    Leuk Lymphoma. 2018;59:1554-1564.
    PubMed     Abstract available


  528. STRATI P, Tang G, Duose DY, Mallampati S, et al
    Myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Leuk Lymphoma. 2018;59:1672-1676.
    PubMed     Abstract available


  529. DASGUPTA Y, Golovine K, Nieborowska-Skorska M, Luo L, et al
    Drugging DNA repair to target T-ALL cells.
    Leuk Lymphoma. 2018;59:1746-1749.
    PubMed    


  530. BURKE MJ, Devidas M, Maloney K, Angiolillo A, et al
    Severe pegaspargase hypersensitivity reaction rates (grade >/=3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
    Leuk Lymphoma. 2018;59:1624-1633.
    PubMed     Abstract available


  531. VAKHARIA P, Nardone B, Budris W, Hoshizaki K, et al
    Blinatumomab and pancreatitis: an analysis of FAERS, EudraVigilance, and a large urban U.S. patient population data.
    Leuk Lymphoma. 2018;59:1759-1761.
    PubMed    


    June 2018
  532. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed    


  533. PODSZYWALOW-BARTNICKA P, Maifrede S, Le BV, Nieborowska-Skorska M, et al
    PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leuk Lymphoma. 2018 Jun 22:1-3. doi: 10.1080/10428194.2018.1471602.
    PubMed    


  534. CHEN CI, Paul H, Le LW, Wei EN, et al
    A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892.
    PubMed     Abstract available


  535. THAN H, Lye WK, Sng C, Allen JC Jr, et al
    BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jun 19:1-4. doi: 10.1080/10428194.2018.1461863.
    PubMed    


  536. CRASSINI K, Pyke T, Shen Y, Stevenson WS, et al
    Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Jun 18:1-12. doi: 10.1080/10428194.2018.1455974.
    PubMed     Abstract available


  537. STRATI P, Gabutti C, Thompson PA, Kontoyiannis DP, et al
    Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-3. doi: 10.1080/10428194.2018.1474527.
    PubMed    


  538. PAPAGEORGIOU SG, Diamantopoulos MA, Kontos CK, Bouchla A, et al
    MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-10. doi: 10.1080/10428194.2018.1461861.
    PubMed     Abstract available


  539. YAMAMOTO K, Yakushijin K, Ichikawa H, Kakiuchi S, et al
    Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7(+)CD56(+) acute myeloid leukemia with t(10;17)(p15;q21).
    Leuk Lymphoma. 2018 Jun 18:1-5. doi: 10.1080/10428194.2018.1464157.
    PubMed    


  540. BERTOLI S, Tavitian S, Berard E, Gadaud N, et al
    Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
    Leuk Lymphoma. 2018 Jun 12:1-4. doi: 10.1080/10428194.2018.1464156.
    PubMed    


  541. HIWASE D, Ross D
    Success is built on failures: tackling the challenge of ponatinib failure.
    Leuk Lymphoma. 2018;59:1279-1281.
    PubMed    


  542. BODDU P, Shah AR, Borthakur G, Verstovsek S, et al
    Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
    Leuk Lymphoma. 2018;59:1312-1322.
    PubMed     Abstract available


  543. BODDU P, Oviedo SP, Rausch CR, Yam C, et al
    PET-CT in AML-related hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2018;59:1486-1489.
    PubMed    


    May 2018
  544. PLEYER C, Wiestner A, Sun C
    Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 May 15:1-9. doi: 10.1080/10428194.2018.1457147.
    PubMed     Abstract available


  545. YOGARAJAH M, Montgomery N, Matson M, Blanchard L, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Leuk Lymphoma. 2018 May 11:1-3. doi: 10.1080/10428194.2018.1459614.
    PubMed    


  546. ALDERUCCIO JP, Mackrides N, Chapman JR, Vega F, et al
    Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.
    Leuk Lymphoma. 2018 May 10:1-4. doi: 10.1080/10428194.2018.1461862.
    PubMed    


  547. OHANIAN M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, et al
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158.
    PubMed     Abstract available


  548. KRULL K, Kunstreich M, Bronsema A, Bleckmann K, et al
    Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
    Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292.
    PubMed     Abstract available


  549. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Abstract available


  550. SATO E, Iriyama N, Tokuhira M, Takaku T, et al
    Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Leuk Lymphoma. 2018;59:1105-1112.
    PubMed     Abstract available


    April 2018
  551. STAHL M, Pine A, Hendrickson JE, Litzow MR, et al
    Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey().
    Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219.
    PubMed    


  552. TAKEI T, Yokoyama K, Shimizu E, Konuma T, et al
    Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.
    Leuk Lymphoma. 2018 Apr 12:1-2. doi: 10.1080/10428194.2018.1443335.
    PubMed    


  553. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Abstract available


  554. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed    


  555. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed    


  556. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed    


  557. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed    


  558. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed    


  559. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Abstract available


  560. BODDU P, Kantarjian H, Garcia-Manero G, Allison J, et al
    The emerging role of immune checkpoint based approaches in AML and MDS.
    Leuk Lymphoma. 2018;59:790-802.
    PubMed     Abstract available


    March 2018
  561. HOVERSTEN K, Vallapureddy R, Lasho T, Finke C, et al
    Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.
    Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212.
    PubMed    


  562. MACDONALD RJ, Bunaciu RP, Ip V, Dai D, et al
    Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452213.
    PubMed     Abstract available


  563. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Abstract available


  564. PRESS KR, Uy N, Keefer J, Gore SD, et al
    Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
    Leuk Lymphoma. 2018;59:755-757.
    PubMed    


  565. HIRAI M, Yagasaki H, Fujimura J, Inoue M, et al
    Successful preemptive donor lymphocyte infusions from a haploidentical donor in a boy with E2A-HLF-positive ALL.
    Leuk Lymphoma. 2018;59:746-748.
    PubMed    


    February 2018
  566. JIANG JG, Xu Y, Wu Z, Ni H, et al
    Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma. 2018 Feb 23:1-3. doi: 10.1080/10428194.2018.1436174.
    PubMed    


  567. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed    


  568. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed    


  569. MOLICA S, Levato L, Mirabelli R, Tedeschi A, et al
    Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436175.
    PubMed    


  570. ROZOVSKI U, Harris DM, Li P, Liu Z, et al
    Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167.
    PubMed     Abstract available


  571. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Abstract available


  572. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed    


  573. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Abstract available


  574. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed    


  575. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed    


  576. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Abstract available


  577. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed    


  578. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed    


  579. HE F, Sapkota S, Parker S, Defor T, et al
    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 7:1-8. doi: 10.1080/10428194.2018.1433297.
    PubMed     Abstract available


  580. FLOWERS CR, Nabhan C, Kay NE, Mato A, et al
    Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study.
    Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860.
    PubMed     Abstract available


  581. TORREBADELL M, Diaz-Beya M, Kalko SG, Pratcorona M, et al
    A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 2:1-11. doi: 10.1080/10428194.2017.1422859.
    PubMed     Abstract available


  582. IMBERT V, Nebout M, Mary D, Endou H, et al
    Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells.
    Leuk Lymphoma. 2018;59:460-468.
    PubMed     Abstract available


  583. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Abstract available


  584. BEZERRA ED, Smith H, Estey E
    A case of indolent AML with five-year survival without treatment.
    Leuk Lymphoma. 2018;59:519.
    PubMed    


  585. KASHOFER K, Gornicec M, Lind K, Caraffini V, et al
    Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.
    Leuk Lymphoma. 2018;59:501-504.
    PubMed    


  586. DANIELZIK T, Koldehoff M, Buttkereit U, Beelen DW, et al
    Sensitive detection of rare antigen-specific T cells directed against Wilms' tumor 1 by FluoroSpot assay.
    Leuk Lymphoma. 2018;59:490-492.
    PubMed    


  587. LAD D, Hoeppli R, Huang Q, Garcia R, et al
    Regulatory T-cells drive immune dysfunction in CLL.
    Leuk Lymphoma. 2018;59:486-489.
    PubMed    


    January 2018
  588. SCIUME M, Fracchiolla NS, Cortelezzi A
    Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jan 31:1-2. doi: 10.1080/10428194.2018.1429603.
    PubMed    


  589. ZHANG Y, Qu S, Wang Q, Li J, et al
    A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Leuk Lymphoma. 2018 Jan 31:1-3. doi: 10.1080/10428194.2018.1427855.
    PubMed    


  590. ANDO T, Kojima K, Sano H, Kidoguchi K, et al
    Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
    Leuk Lymphoma. 2018 Jan 31:1-4. doi: 10.1080/10428194.2018.1427859.
    PubMed    


  591. RICARD L, Abisror N, Droin N, Selimoglu-Buet D, et al
    Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2018 Jan 25:1-3. doi: 10.1080/10428194.2018.1427857.
    PubMed    


  592. PANDEY G, Bakhshi S, Thakur B, Jain P, et al
    Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 18:1-13. doi: 10.1080/10428194.2017.1422865.
    PubMed     Abstract available


  593. GUILLEM V, Calabuig M, Brunet S, Esteve J, et al
    Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
    Leuk Lymphoma. 2018 Jan 18:1-11. doi: 10.1080/10428194.2017.1422858.
    PubMed     Abstract available


  594. LENNMYR EB, Kozlowski P, Ahlberg L, Bernell P, et al
    Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.
    Leuk Lymphoma. 2018 Jan 18:1-4. doi: 10.1080/10428194.2017.1416369.
    PubMed    


  595. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.
    PubMed    


  596. BODDU P, Kantarjian H, Ravandi F, Garcia-Manero G, et al
    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864.
    PubMed    


  597. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed    


  598. YANG M, Xing S, Ou HL, Zhang L, et al
    Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS.
    Leuk Lymphoma. 2018 Jan 16:1-9. doi: 10.1080/10428194.2017.1421754.
    PubMed     Abstract available


  599. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Abstract available


  600. ZHOU H, Xu RZ, Gu Y, Shi PF, et al
    Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 15:1-13. doi: 10.1080/10428194.2017.1390229.
    PubMed     Abstract available


  601. SHAO H, Zeng Z, Cen J, Zhang J, et al
    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Leuk Lymphoma. 2018 Jan 15:1-7. doi: 10.1080/10428194.2017.1422860.
    PubMed     Abstract available


  602. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed    


  603. HANNON M, Wilde L, Nwaoduah N, Kasner M, et al
    Chronic myelomonocytic leukemia with central nervous system involvement.
    Leuk Lymphoma. 2018 Jan 11:1-2. doi: 10.1080/10428194.2017.1422866.
    PubMed    


  604. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Abstract available


  605. RUAN J, Gao S, Yang J, Li H, et al
    WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells.
    Leuk Lymphoma. 2018;59:162-170.
    PubMed     Abstract available


  606. GUO BB, Liang J, Allcock RJN, Mirzai B, et al
    A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
    Leuk Lymphoma. 2018;59:245-248.
    PubMed    


  607. JANAKIRAM M, Verma A, Wang Y, Budhathoki A, et al
    Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
    Leuk Lymphoma. 2018;59:241-244.
    PubMed    


  608. ZHANG Y, Cheng Z, Yan WZ, Liu SF, et al
    Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
    Leuk Lymphoma. 2018;59:233-236.
    PubMed    


    December 2017
  609. HANIF A, Wang ES, Thompson JE, Baron JI, et al
    Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595.
    PubMed    


  610. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Abstract available


  611. GAY ND, Kozin E, Okada C, Danilov AV, et al
    Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1410890.
    PubMed    


  612. HALDER A, Nayak KB, Chakraborty S
    Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1406089.
    PubMed    


  613. LI H, Zhang W, Kuang P, Ye Y, et al
    Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Dec 7:1-9. doi: 10.1080/10428194.2017.1406933.
    PubMed     Abstract available


  614. HERNANDEZ-GONZALEZ O, Ortiz-Zamudio JJ, Rodriguez-Pinal CJ, Alvarado-Morales I, et al
    Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1406090.
    PubMed     Abstract available


  615. LEI H, Wang W, Wu Y
    Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1403600.
    PubMed     Abstract available


  616. GUPTA SK, Bakhshi S, Chopra A, Kamal VK, et al
    Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1408087.
    PubMed     Abstract available


  617. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed    



  618. XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York.
    Leuk Lymphoma. 2017;58.
    PubMed    


    November 2017
  619. RUGGIU M, Oberkampf F, Ghez D, Cony-Makhoul P, et al
    Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Nov 28:1-7. doi: 10.1080/10428194.2017.1397666.
    PubMed     Abstract available


  620. RIBERA JM, Morgades M, Montesinos P, Martino R, et al
    Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661.
    PubMed     Abstract available


  621. KANNA R, Choudhary G, Ramachandra N, Steidl U, et al
    STAT3 inhibition as a therapeutic strategy for leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668.
    PubMed     Abstract available


  622. PEI R, Si T, Lu Y, Zhou JX, et al
    Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-9. doi: 10.1080/10428194.2017.1399314.
    PubMed     Abstract available


  623. GOHIL SH, Maciocia N, Patrick P, Roberts T, et al
    LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399311.
    PubMed    


  624. PATNAIK MM
    The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-14. doi: 10.1080/10428194.2017.1399312.
    PubMed     Abstract available


  625. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed    


  626. AYED AO, Parikh SA
    Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leuk Lymphoma. 2017 Nov 8:1-10. doi: 10.1080/10428194.2017.1397665.
    PubMed     Abstract available


  627. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Abstract available


  628. MCCURDY SR, Levis MJ
    Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 2:1-19. doi: 10.1080/10428194.2017.1393669.
    PubMed     Abstract available


    October 2017
  629. SATO R, Jacob J, Gaballa S
    Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1387907.
    PubMed    


  630. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Abstract available


  631. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Abstract available


  632. SALZER W, Bostrom B, Messinger Y, Perissinotti AJ, et al
    Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305.
    PubMed     Abstract available


  633. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Abstract available


  634. GEYER MB, Manjunath SH, Evans AG, Park JH, et al
    Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Leuk Lymphoma. 2017 Oct 18:1-5. doi: 10.1080/10428194.2017.1390237.
    PubMed    


  635. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Abstract available


  636. MITSUI-SEKINAKA K, Sekinaka Y, Ogura Y, Honda M, et al
    A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
    Leuk Lymphoma. 2017 Oct 18:1-3. doi: 10.1080/10428194.2017.1387901.
    PubMed    


  637. CORROCHER FA, Bueno de Paiva L, Duarte ASS, Ferro KP, et al
    Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Oct 17:1-4. doi: 10.1080/10428194.2017.1387900.
    PubMed    


  638. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Abstract available


  639. LEE LJ, Toze CL, Huang SJT, Gillan TL, et al
    Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Leuk Lymphoma. 2017 Oct 16:1-8. doi: 10.1080/10428194.2017.1387904.
    PubMed     Abstract available


  640. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Abstract available


  641. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed    


  642. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Abstract available


    September 2017
  643. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed    


  644. APPLEBY N, O'Brien D, Quinn FM, Smyth L, et al
    Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-
    Leuk Lymphoma. 2017 Sep 19:1-10. doi: 10.1080/10428194.2017.1376746.
    PubMed     Abstract available


  645. ANDRITSOS LA, Grieselhuber NR, Anghelina M, Rogers KA, et al
    Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-4. doi: 10.1080/10428194.2017.1365853.
    PubMed    


  646. KREINITZ N, Polliack A, Tadmor T
    Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?
    Leuk Lymphoma. 2017 Sep 18:1-2. doi: 10.1080/10428194.2017.1376748.
    PubMed    


  647. RIZZOTTO L, Lai TH, Bottoni A, Woyach JA, et al
    Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-5. doi: 10.1080/10428194.2017.1376742.
    PubMed    


  648. VLIJM-KIEVIT A, Jorna NGE, Moll E, Pajkrt E, et al
    Acute lymphoblastic leukemia during the third trimester of pregnancy.
    Leuk Lymphoma. 2017 Sep 15:1-3. doi: 10.1080/10428194.2017.1375104.
    PubMed    


  649. MULANOVICH V, Kontoyiannis DP
    Acute myeloid leukemia and the infectious diseases consultant.
    Leuk Lymphoma. 2017 Sep 15:1-8. doi: 10.1080/10428194.2017.1365861.
    PubMed     Abstract available


  650. MESCHER C, Gilbertson D, Randall NM, Tarchand G, et al
    The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
    Leuk Lymphoma. 2017 Sep 14:1-8. doi: 10.1080/10428194.2017.1375109.
    PubMed     Abstract available


  651. VAUGHN JL, Kline D, Denlinger NM, Andritsos LA, et al
    Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
    Leuk Lymphoma. 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744.
    PubMed    


  652. TAVARES M, Lemiale V, Mokart D, Pene F, et al
    Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375106.
    PubMed     Abstract available


  653. PULA A, Stawiski K, Braun M, Iskierka-Jazdzewska E, et al
    Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Leuk Lymphoma. 2017 Sep 11:1-11. doi: 10.1080/10428194.2017.1375101.
    PubMed     Abstract available


  654. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Abstract available


  655. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Abstract available


  656. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed    


  657. GURBUXANI S
    The web of microRNA in B lymphoblastic leukemia.
    Leuk Lymphoma. 2017;58:2024-2025.
    PubMed    


    August 2017
  658. HUANG A, Huang C, Tang G, Cheng H, et al
    Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Aug 31:1-11. doi: 10.1080/10428194.2017.1369072.
    PubMed     Abstract available


  659. BURGSTALLER S, Stauder R, Kuehr T, Lang A, et al
    A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Leuk Lymphoma. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070.
    PubMed     Abstract available


  660. CAO H, Xie J, Guo L, Han K, et al
    All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Aug 29:1-9. doi: 10.1080/10428194.2017.1365850.
    PubMed     Abstract available


  661. BODDU P, Kantarjian H, Garcia-Manero G, Ravandi F, et al
    Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 25:1-4. doi: 10.1080/10428194.2017.1365857.
    PubMed    


  662. FALANTES J, Pleyer L, Thepot S, Almeida AM, et al
    Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Leuk Lymphoma. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854.
    PubMed     Abstract available


  663. IACCARINO L, Ottone T, Hasan SK, Divona M, et al
    Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2017 Aug 24:1-3. doi: 10.1080/10428194.2017.1369067.
    PubMed    


  664. SI T, Lu Y, Li F, Jiang L, et al
    High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 24:1-7. doi: 10.1080/10428194.2017.1324157.
    PubMed     Abstract available



  665. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed    


  666. CRUZ NM, Sugita M, Ewing-Crystal N, Lam L, et al
    Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 10:1-5. doi: 10.1080/10428194.2017.1361023.
    PubMed    


  667. JALBUT MM, Brunner AM, Amrein PC, Ballen KK, et al
    Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361028.
    PubMed    


  668. CHEN X, Dou H, Wang X, Huang Y, et al
    KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1361025.
    PubMed     Abstract available


  669. CAYSSIALS E, Tartarin F, Guilhot J, Sorel N, et al
    Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1357178.
    PubMed    


  670. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Abstract available


  671. KIVIOJA JL, Lopez Marti JM, Kumar A, Kontro M, et al
    Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
    PubMed     Abstract available


  672. DIRSE V, Norvilas R, Gineikiene E, Matuzeviciene R, et al
    ETV6 and NOTCH1 germline variants in adult acute leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-3. doi: 10.1080/10428194.2017.1359742.
    PubMed    


  673. SESE L, Rivaud E, Bron C, Leblond V, et al
    Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-4. doi: 10.1080/10428194.2017.1357170.
    PubMed    


  674. MULCAHY A, Mulligan SP, Shumack SP
    Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1349903.
    PubMed    


  675. WANG A, Cai X, Qiang P, Duan Q, et al
    Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
    Leuk Lymphoma. 2017 Aug 1:1-3. doi: 10.1080/10428194.2017.1357176.
    PubMed    


    July 2017
  676. YANADA M, Mori J, Aoki J, Harada K, et al
    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma. 2017 Jul 28:1-9. doi: 10.1080/10428194.2017.1357173.
    PubMed     Abstract available


  677. GEYER MB, Tallman MS
    Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.
    Leuk Lymphoma. 2017 Jul 28:1-3. doi: 10.1080/10428194.2017.1355971.
    PubMed    


  678. KONG J, Zhao XS, Qin YZ, Zhu HH, et al
    The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 26:1-6. doi: 10.1080/10428194.2017.1352091.
    PubMed     Abstract available


  679. ALDOSS I, Stein AS
    Advances in adult acute lymphoblastic leukemia therapy.
    Leuk Lymphoma. 2017 Jul 26:1-18. doi: 10.1080/10428194.2017.1354372.
    PubMed     Abstract available


  680. STRICKLER N, Balabanov S, Casauro K, Schanz U, et al
    Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
    Leuk Lymphoma. 2017 Jul 21:1-8. doi: 10.1080/10428194.2017.1352090.
    PubMed     Abstract available


  681. GONZALEZ-GASCON Y MARIN I, Hernandez-Sanchez M, Rodriguez-Vicente AE, Puiggros A, et al
    Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jul 21:1-10. doi: 10.1080/10428194.2017.1349901.
    PubMed     Abstract available


  682. ENGLAND JT, Leitch HA
    Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349904.
    PubMed    


  683. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Abstract available


  684. ALLAN JN, Roboz GJ, Askin G, Ritchie E, et al
    CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1352089.
    PubMed     Abstract available


  685. SHORT NJ, Kantarjian H, Ravandi F, Huang X, et al
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
    PubMed     Abstract available


  686. RAUSCH CR, Marini BL, Benitez LL, Elias A, et al
    PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia dagger.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349902.
    PubMed     Abstract available


  687. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Abstract available


  688. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Abstract available


  689. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Abstract available


  690. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Abstract available


  691. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed    


  692. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed    


  693. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed    


  694. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Abstract available


  695. CALVELLO C, Rocca B, Klersy C, Zappatore R, et al
    Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1346252.
    PubMed     Abstract available


  696. SALMOIRAGHI S, Rambaldi A, Spinelli O
    TP53 in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-12. doi: 10.1080/10428194.2017.1344839.
    PubMed     Abstract available


  697. XU W, Li X, Quan L, Yao J, et al
    Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-10. doi: 10.1080/10428194.2017.1346253.
    PubMed     Abstract available


  698. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Abstract available


  699. XU L, Zhang M, Li H, Guan W, et al
    SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-13. doi: 10.1080/10428194.2017.1344843.
    PubMed     Abstract available


    June 2017
  700. KATKISH LA, Rangaraju S, Rector TS, Gravely AA, et al
    Incidence of unprovoked venous thromboembolic events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 27:1-3. doi: 10.1080/10428194.2017.1341979.
    PubMed    


  701. SANDOVAL-SUS JD, Chavez JC, Dalia S, Naqvi SMH, et al
    Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1323271.
    PubMed     Abstract available


  702. BORUTINSKAITE V, Virksaite A, Gudelyte G, Navakauskiene R, et al
    Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1339881.
    PubMed     Abstract available


  703. MAFFEI R, Fiorcari S, Martinelli S, Benatti S, et al
    Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Leuk Lymphoma. 2017 Jun 22:1-11. doi: 10.1080/10428194.2017.1339872.
    PubMed     Abstract available


  704. SANIKOMMU SR, Clemente MJ, Chomczynski P, Afable MG 2nd, et al
    Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).
    Leuk Lymphoma. 2017 Jun 20:1-7. doi: 10.1080/10428194.2017.1339880.
    PubMed     Abstract available


  705. VILLEMAGNE SANCHEZ LA, O'Callaghan C, Gough K, Hall K, et al
    Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 15:1-10. doi: 10.1080/10428194.2017.1337114.
    PubMed     Abstract available


  706. KANSAGRA A, Dahiya S, Litzow M
    Continuing challenges and current issues in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jun 11:1-16. doi: 10.1080/10428194.2017.1335397.
    PubMed     Abstract available


  707. FARSHCHI ZARABI S, Chan S, Gupta V, Khalaf D, et al
    Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
    Leuk Lymphoma. 2017 Jun 9:1-4. doi: 10.1080/10428194.2017.1323273.
    PubMed    


  708. DROIN N, Lucas N, Parinet V, Selimoglu-Buet D, et al
    Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.
    Leuk Lymphoma. 2017 Jun 8:1-5. doi: 10.1080/10428194.2017.1330468.
    PubMed     Abstract available


  709. LARSEN CM, Villarraga HR, Begna KH, Litzow MR, et al
    Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1323268.
    PubMed    


  710. TIONG IS, Tan P, McManus J, Cummings N, et al
    Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1334122.
    PubMed    


  711. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed    


  712. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323267.
    PubMed     Abstract available


  713. BHATT VR, Gundabolu K, Koll T, Maness LJ, et al
    Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1323275.
    PubMed     Abstract available


  714. SOLE C, Martinez D, Gine E, Gonzalez-Farre B, et al
    Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-4. doi: 10.1080/10428194.2017.1330470.
    PubMed    


  715. NGUYEN D, Haley L, Pallavajjala A, Gojo I, et al
    Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1324163.
    PubMed    


  716. WEBSTER JA, Pratz KW
    Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Leuk Lymphoma. 2017 Jun 2:1-14. doi: 10.1080/10428194.2017.1330956.
    PubMed     Abstract available


  717. WENDTNER CM, Gregor M
    Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 1:1-11. doi: 10.1080/10428194.2017.1330474.
    PubMed     Abstract available


  718. PIGGIN A, Bayly E, Tam CS
    Novel agents versus chemotherapy as frontline treatment of CLL.
    Leuk Lymphoma. 2017;58:1320-1324.
    PubMed     Abstract available


    May 2017
  719. GAFTER-GVILI A
    G6PD deficiency and fungal infections in patients with acute myeloid leukemia: less enzyme more fungus.
    Leuk Lymphoma. 2017 May 31:1-2. doi: 10.1080/10428194.2017.1330478.
    PubMed    


  720. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596.
    PubMed     Abstract available


  721. LEE SE, Choi SY, Kim SH, Song HY, et al
    Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
    Leuk Lymphoma. 2017 May 25:1-9. doi: 10.1080/10428194.2017.1320711.
    PubMed     Abstract available


  722. SAINI L, Brandwein J, Szkotak A, Ghosh S, et al
    Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-8. doi: 10.1080/10428194.2017.1326032.
    PubMed     Abstract available


  723. XU X, Nagel S, Quentmeier H, Wang Z, et al
    KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-10. doi: 10.1080/10428194.2017.1324156.
    PubMed     Abstract available


  724. HOSHINO T, Taki T, Takada S, Hatsumi N, et al
    Spontaneous remission of adult acute myeloid leukemia with t(8;16)(p11;p13)/MOZ-CBP fusion.
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1320712.
    PubMed    


  725. BRECCIA M, Efficace F
    Are chronic myeloid leukemia patients ready to stop long-term treatment?
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1330476.
    PubMed    


  726. LARSON RA
    Managing CNS disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 23:1-11. doi: 10.1080/10428194.2017.1326597.
    PubMed     Abstract available


  727. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Abstract available


  728. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed    


  729. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed    


  730. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Abstract available


  731. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Abstract available


  732. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed    


  733. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Abstract available


  734. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Abstract available


  735. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Abstract available


  736. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Abstract available


    April 2017
  737. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed    


  738. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Abstract available


  739. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Abstract available


  740. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Abstract available


  741. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Abstract available


  742. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Abstract available


  743. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed    


  744. BEAUPIN LK, Bostrom B, Barth MJ, Franklin I, et al
    Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Leuk Lymphoma. 2017;58:766-772.
    PubMed     Abstract available


    March 2017
  745. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Abstract available


  746. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed    


  747. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Abstract available


    January 2016
  748. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: